Cover Page
Cover Page - shares | 3 Months Ended | |
Mar. 31, 2021 | May 04, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-34885 | |
Entity Registrant Name | AMYRIS, INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 55-0856151 | |
Entity Address, Address Line One | 5885 Hollis Street | |
Entity Address, Address Line Two | Suite 100 | |
Entity Address, City or Town | Emeryville | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94608 | |
City Area Code | 510 | |
Local Phone Number | 450-0761 | |
Title of 12(b) Security | Common Stock, $0.0001 par value per share | |
Trading Symbol | AMRS | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Accelerated Filer | |
Entity Emerging Growth Company | false | |
Entity Small Business | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding (in shares) | 291,471,055 | |
Entity Central Index Key | 0001365916 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 143,821 | $ 30,152 |
Restricted cash | 283 | 309 |
Accounts receivable, net of allowance of $154 and $137, respectively | 27,036 | 32,846 |
Accounts receivable - related party, net of allowance of $0 and $0, respectively | 391 | 12,110 |
Contract assets | 6,589 | 4,178 |
Contract assets - related party | 2,000 | 1,203 |
Inventories | 47,639 | 42,862 |
Deferred cost of products sold - related party | 5,220 | 9,801 |
Prepaid expenses and other current assets | 19,246 | 13,103 |
Total current assets | 252,225 | 146,564 |
Property, plant and equipment, net | 31,933 | 32,875 |
Deferred cost of products sold, noncurrent - related party | 9,391 | 9,939 |
Restricted cash, noncurrent | 961 | 961 |
Recoverable taxes from Brazilian government entities | 8,680 | 8,641 |
Right-of-use assets under financing leases, net | 9,296 | 9,994 |
Right-of-use assets under operating leases, net | 9,333 | 10,136 |
Other assets | 4,770 | 3,704 |
Total assets | 326,589 | 222,814 |
Current liabilities: | ||
Accounts payable | 44,154 | 41,045 |
Accrued and other current liabilities | 32,121 | 30,707 |
Financing lease liabilities | 3,258 | 4,170 |
Operating lease liabilities | 5,510 | 5,226 |
Contract liabilities | 6,163 | 4,468 |
Debt, current portion (includes instrument measured at fair value of $54,757 and $53,387, respectively) | 55,904 | 54,748 |
Related party debt, current portion | 0 | 22,689 |
Total current liabilities | 147,110 | 163,053 |
Long-term debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively) | 13,873 | 26,170 |
Related party debt, net of current portion (includes instrument measured at fair value of $0 and $0, respectively) | 413,687 | 159,452 |
Operating lease liabilities, net of current portion | 8,209 | 9,732 |
Derivative liabilities | 31,384 | 8,698 |
Other noncurrent liabilities | 22,467 | 22,754 |
Total liabilities | 636,730 | 389,859 |
Commitments and contingencies | ||
Mezzanine equity: Contingently redeemable common stock | 5,000 | 5,000 |
Stockholders’ deficit: | ||
Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 8,280 shares issued and outstanding as of March 31, 2021 and December 31, 2020 | 0 | 0 |
Common stock - $0.0001 par value, 350,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 273,266,917 and 244,951,446 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively | 27 | 24 |
Additional paid-in capital | 2,106,214 | 1,957,224 |
Accumulated other comprehensive loss | (49,413) | (47,375) |
Accumulated deficit | (2,377,943) | (2,086,692) |
Total Amyris, Inc. stockholders’ deficit | (321,115) | (176,819) |
Noncontrolling interest | 5,974 | 4,774 |
Total stockholders' deficit | (315,141) | (172,045) |
Total liabilities, mezzanine equity and stockholders' deficit | $ 326,589 | $ 222,814 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Accounts receivable, allowance | $ 154 | $ 137 |
Accounts receivable, allowance, related parties | 0 | 0 |
Fair value of debt | 54,757 | 53,387 |
Fair value of long-term debt | 0 | 0 |
Related party debt, net, fair value | $ 0 | $ 0 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 8,280 | 8,280 |
Preferred stock, shares outstanding (in shares) | 8,280 | 8,280 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 350,000,000 | 350,000,000 |
Common stock, shares issued (in shares) | 273,266,917 | 273,266,917 |
Common stock, shares outstanding (in shares) | 244,951,446 | 244,951,446 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Revenue: | ||
Revenue | $ 176,859 | $ 29,130 |
Cost and operating expenses: | ||
Cost of products sold | 22,659 | 11,790 |
Research and development | 23,332 | 17,126 |
Sales, general and administrative | 37,922 | 32,014 |
Total cost and operating expenses | 83,913 | 60,930 |
Income (loss) from operations | 92,946 | (31,800) |
Other income (expense): | ||
Interest expense | (5,813) | (15,002) |
(Loss) gain from change in fair value of derivative instruments | (22,745) | 3,282 |
Loss from change in fair value of debt | (326,785) | (16,503) |
Loss upon extinguishment of debt | (27,313) | (27,319) |
Other (expense) income, net | (678) | 4 |
Total other expense, net | (383,334) | (55,538) |
Loss before income taxes and loss from investment in affiliate | (290,388) | (87,338) |
Provision for income taxes | (55) | (91) |
Gain (loss) from investment in affiliate | 392 | (415) |
Net loss | (290,051) | (87,844) |
Less: income attributable to noncontrolling interest in Aprinnova | (1,200) | 0 |
Net loss attributable to Amyris, Inc. | (291,251) | (87,844) |
Less: losses allocated to participating securities | 2,099 | 1,087 |
Net loss attributable to Amyris, Inc. common stockholders, diluted | (289,152) | (86,757) |
Net loss attributable to Amyris, Inc. common stockholders, basic | $ (289,152) | $ (86,757) |
Earnings Per Share, Basic [Abstract] | ||
Loss per share attributable to common stockholders, basic (in dollars per share) | $ (1.08) | $ (0.56) |
Loss per share attributable to common stockholders, diluted (in dollars per share) | $ (1.08) | $ (0.56) |
Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted (in shares) | 267,733,555 | 155,065,635 |
Product | ||
Revenue: | ||
Revenue | $ 28,179 | $ 17,854 |
Licenses and Royalties | ||
Revenue: | ||
Revenue | 143,800 | 5,161 |
Grants and Collaborations | ||
Revenue: | ||
Revenue | $ 4,880 | $ 6,115 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Operations (Parentheticals) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Revenues, related party | $ 147,274 | $ 6,817 |
Product | ||
Revenues, related party | 1,662 | 49 |
Licenses and Royalties | ||
Revenues, related party | 143,612 | 3,750 |
Grants and Collaborations | ||
Revenues, related party | $ 2,000 | $ 3,018 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Comprehensive loss: | ||
Net loss | $ (290,051) | $ (87,844) |
Foreign currency translation adjustment | (2,038) | (2,549) |
Total comprehensive loss | (292,089) | (90,393) |
Less: income attributable to noncontrolling interest in Aprinnova | (1,200) | 0 |
Comprehensive loss attributable to Amyris, Inc. | $ (293,289) | $ (90,393) |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity - USD ($) $ in Thousands | Total | Senior convertible notesConvertible notes payable | Preferred Stock | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Noncontrolling Interest | Total Stockholders' Deficit | Mezzanine Equity - Common Stock |
Balance (in shares) at Dec. 31, 2019 | 8,280 | 117,742,677 | ||||||||
Balance at Dec. 31, 2019 | $ 0 | $ 12 | $ 1,543,668 | $ (43,804) | $ (1,755,653) | $ 609 | $ (255,168) | $ 5,000 | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares) | 495,581 | |||||||||
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock | (8) | (8) | ||||||||
Issuance of common stock and warrants upon conversion of debt principal (in shares) | 6,337,594 | |||||||||
Issuance of common stock and warrants upon conversion of debt principal | $ 1 | 21,259 | 21,260 | |||||||
Issuance of common stock upon exercise of warrants (in shares) | 1,160,929 | |||||||||
Issuance of common stock upon exercise of warrants | 3,332 | 3,332 | ||||||||
Issuance of common stock upon exercise of warrants - related party (in shares) | 24,165,166 | |||||||||
Issuance of common stock upon exercise of warrants - related party | $ 2 | 68,763 | 68,765 | |||||||
Issuance of common stock in private placement (in shares) | 3,484,321 | |||||||||
Issuance of common stock in private placement | 10,000 | 10,000 | ||||||||
Issuance of common stock in private placement - related party (in shares) | 10,505,652 | |||||||||
Issuance of common stock in private placement - related party | $ 1 | 27,188 | 27,189 | |||||||
Exercise of common stock rights warrant - related party | 15,000 | 15,000 | ||||||||
Issuance of common stock right warrant - related party | 8,904 | 8,904 | ||||||||
Modification of previously issued common stock warrants | 1,286 | 1,286 | ||||||||
Derecognition of liability warrants to equity | 5,200 | 5,200 | ||||||||
Stock-based compensation | 3,504 | 3,504 | ||||||||
Foreign currency translation adjustment | (2,549) | (2,549) | ||||||||
Net loss attributable to Amyris, Inc. | $ (87,844) | (87,844) | (87,844) | |||||||
Balance (in shares) at Mar. 31, 2020 | 8,280 | 163,891,920 | ||||||||
Balance at Mar. 31, 2020 | $ 0 | $ 16 | 1,708,096 | (46,353) | (1,843,497) | 609 | (181,129) | 5,000 | ||
Balance (in shares) at Dec. 31, 2020 | 8,280 | 244,951,446 | ||||||||
Balance at Dec. 31, 2020 | $ (172,045) | $ 0 | $ 24 | 1,957,224 | (47,375) | (2,086,692) | 4,774 | (172,045) | 5,000 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock (in shares) | 496,341 | |||||||||
Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement of restricted stock | (2) | (2) | ||||||||
Issuance of common stock and warrants upon conversion of debt principal (in shares) | 5,827,164 | |||||||||
Issuance of common stock and warrants upon conversion of debt principal | $ 1 | 110,574 | 110,575 | |||||||
Issuance of common stock upon exercise of stock options (in shares) | 375,390 | 377,542 | ||||||||
Issuance of common stock upon exercise of stock options | 1,920 | 1,920 | ||||||||
Issuance of common stock upon exercise of warrants (in shares) | 24,800,000 | 15,557,480 | ||||||||
Issuance of common stock upon exercise of warrants | $ 2 | 32,217 | 32,219 | |||||||
Issuance of common stock upon exercise of warrants - related party (in shares) | 6,056,944 | |||||||||
Issuance of common stock upon exercise of warrants - related party | $ 0 | 0 | 0 | |||||||
Stock-based compensation | 4,281 | 4,281 | ||||||||
Foreign currency translation adjustment | (2,038) | (2,038) | ||||||||
Net loss attributable to Amyris, Inc. | $ (291,251) | (291,251) | 1,200 | (290,051) | ||||||
Balance (in shares) at Mar. 31, 2021 | 8,280 | 273,266,917 | ||||||||
Balance at Mar. 31, 2021 | $ (315,141) | $ 0 | $ 27 | $ 2,106,214 | $ (49,413) | $ (2,377,943) | $ 5,974 | $ (315,141) | $ 5,000 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||||
Shares to be returned per agreement (in shares) | 2,600,000 |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Operating activities | ||
Net loss | $ (290,051) | $ (87,844) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
(Gain) loss from change in fair value of debt | 326,785 | 16,503 |
Loss upon extinguishment of debt | 27,313 | 27,319 |
(Gain) loss from change in fair value of derivative instruments | 22,745 | (3,282) |
Stock-based compensation | 4,281 | 3,504 |
Depreciation and amortization | 2,114 | 1,719 |
Amortization of right-of-use assets under operating leases | 750 | 668 |
Accretion of debt discount | 713 | 1,292 |
(Gain) loss on foreign currency exchange rates | 408 | (109) |
Other | 0 | 42 |
(Gain) loss from investment in affiliate | (392) | 415 |
Changes in assets and liabilities: | ||
Accounts receivable | 17,275 | (5,209) |
Contract assets | (3,208) | (870) |
Inventories | (5,686) | (4,392) |
Deferred cost of products sold - related party | 5,129 | 142 |
Prepaid expenses and other assets | (8,207) | (1,430) |
Accounts payable | 4,154 | 318 |
Accrued and other liabilities | 4,011 | 4,009 |
Lease liabilities | (1,185) | (1,043) |
Contract liabilities | 1,702 | 1,873 |
Net cash provided by (used in) operating activities | 108,651 | (46,375) |
Investing activities | ||
Purchases of property, plant and equipment | (2,493) | (1,040) |
Net cash used in investing activities | (2,493) | (1,040) |
Financing activities | ||
Issuance costs incurred in connection with debt modification | (2,500) | 0 |
Payment of minimum employee taxes withheld upon net share settlement of restricted stock units | (2) | (8) |
Principal payments on debt | (23,196) | (6,981) |
Principal payments on financing leases | (912) | (866) |
Proceeds from exercise of common stock rights warrant - related party | 0 | 15,000 |
Proceeds from exercises of common stock options | 1,920 | 0 |
Proceeds from exercises of warrants | 32,219 | 3,332 |
Proceeds from exercises of warrants - related party | 0 | 13,998 |
Proceeds from issuance of common and preferred stock in private placement, net of issuance costs | 0 | 10,000 |
Proceeds from issuance of common and preferred stock in private placement, net of issuance costs - related party | 0 | 15,000 |
Proceeds from issuance of debt, net of issuance costs | 0 | 188 |
Net cash provided by financing activities | 7,529 | 49,663 |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (44) | 19 |
Net increase in cash, cash equivalents and restricted cash | 113,643 | 2,267 |
Cash, cash equivalents and restricted cash at beginning of period | 31,422 | 1,699 |
Cash, cash equivalents and restricted cash at end of the period | 145,065 | 3,966 |
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets | ||
Cash and cash equivalents | 143,821 | 2,607 |
Restricted cash, current | 283 | 399 |
Restricted cash, noncurrent | 961 | 960 |
Total cash, cash equivalents and restricted cash | 145,065 | 3,966 |
Supplemental disclosures of cash flow information: | ||
Cash paid for interest | 3,275 | 3,152 |
Supplemental disclosures of non-cash investing and financing activities: | ||
Accrued interest added to debt principal | 0 | 1,527 |
Derecognition of derivative liabilities to equity upon extinguishment of debt | 59 | 0 |
Derecognition of derivative liabilities upon exercise of warrants | 0 | 5,200 |
Exercise of common stock warrants in exchange for debt principal and accrued interest reduction | 0 | 69,918 |
Fair value of embedded features in connection with private placement | 0 | 2,962 |
Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances | 0 | 188 |
Fair value of warrants and embedded features recorded as debt discount in connection with debt issuances - related party | 0 | 747 |
Issuance of common stock and warrants upon conversion of debt principal and accrued interest | 110,575 | 18,333 |
Unpaid property, plant and equipment balances in accounts payable and accrued liabilities at end of period | $ 1,121 | $ 1,307 |
Condensed Consolidated Statem_6
Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Parentheticals) - shares | Feb. 04, 2021 | Mar. 31, 2021 |
Senior convertible notes | Convertible notes payable | ||
Shares to be returned per agreement (in shares) | 2,600,000 | 2,600,000 |
Basis of Presentation and Summa
Basis of Presentation and Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation and Summary of Significant Accounting Policies | Basis of Presentation and Summary of Significant Accounting Policies As a leading synthetic biotechnology company active in the Clean Health and Beauty markets through our consumer brands and a top supplier of sustainable and natural ingredients, Amyris, Inc. and our subsidiaries (collectively, Amyris or the Company) apply the Company's proprietary Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products. The Company does so with the use of computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. The Company's biotechnology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that the Company manufactures at industrial scale. Through the combination of our biotechnology platform and our industrial fermentation process, the Company has successfully developed, produced and commercialized many distinct molecules. The accompanying unaudited condensed consolidated financial statements of Amyris, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 (the 2020 Form 10-K), from which the condensed consolidated balance sheet as of December 31, 2020 is derived. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. Significant Accounting Policies Note 1, "Basis of Presentation and Summary of Significant Accounting Policies", to the audited consolidated financial statements in the 2020 Form 10-K includes a discussion of the significant accounting policies and estimates used in the preparation of the Company’s condensed consolidated financial statements. There have been no material changes to the Company's significant accounting policies and estimates during the three months ended March 31, 2021. Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant accounting policies below or specifically discussed in the Notes to Consolidated Financial Statements where such transactions are disclosed. Accounting Standards or Updates Recently Adopted In the three months ended March 31, 2021, the Company adopted these accounting standards or updates: Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) . The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 202 1. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements. Equity Securities, Equity-method Investments and Certain Derivative s In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 . The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements. Accounting Standards or Updates Not Yet Adopted Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments . ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. ASU 2016-13 will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures. Convertible Debt, and Derivatives and Hedging In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures. |
Balance Sheet Details
Balance Sheet Details | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Balance Sheet Details | Balance Sheet Details Allowance for Doubtful Accounts (In thousands) Balance at Beginning of Year Provisions Write-offs, Net Balance at End of Period Three months ended March 31, 2021 $ 137 $ 17 $ — $ 154 Three months ended March 31, 2020 $ 45 $ — $ — $ 45 Inventories (In thousands) March 31, 2021 December 31, 2020 Raw materials $ 12,185 $ 11,800 Work-in-process 8,702 10,760 Finished goods 26,752 20,302 Inventories $ 47,639 $ 42,862 Deferred cost of products sold - related party (In thousands) March 31, 2021 December 31, 2020 Deferred cost of products sold - related party $ 5,220 $ 9,801 Deferred cost of products sold, noncurrent - related party 9,391 9,939 Total $ 14,611 $ 19,740 Amounts reported as "Deferred cost of products sold - related party" are in connection with an agreement with Koninklijke DSM N.V. (DSM) under which DSM will provide capacity for sweetener production at DSM's Brotas, Brazil manufacturing facility through December 2022. Deferred cost of products sold asset is being expensed to cost of products sold on a units of production basis as the Company's sweetener product is sold over the five Prepaid expenses and other current assets (In thousands) March 31, 2021 December 31, 2020 Prepayments, advances and deposits $ 13,453 $ 6,637 Non-inventory production supplies 3,364 3,989 Recoverable taxes from Brazilian government entities 1,020 1,063 Other 1,409 1,414 Total prepaid expenses and other current assets $ 19,246 $ 13,103 Property, Plant and Equipment, Net (In thousands) March 31, 2021 December 31, 2020 Machinery and equipment $ 49,880 $ 50,415 Leasehold improvements 44,800 45,197 Computers and software 7,362 6,741 Furniture and office equipment, vehicles and land 3,450 3,507 Construction in progress 7,238 7,250 112,730 113,110 Less: accumulated depreciation and amortization (80,797) (80,235) Property, plant and equipment, net $ 31,933 $ 32,875 During the three months ended March 31, 2021 and 2020, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows: Three Months Ended March 31, (In thousands) 2021 2020 Depreciation and amortization expense $ 2,114 $ 1,719 Leases Operating Leases The Company has operating leases primarily for administrative offices, laboratory equipment and other facilities. The operating leases have remaining terms that range from 1 to 5 years, and often include one or more options to renew. These renewal terms can extend the lease term from 1 to 5 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. The operating leases are classified as ROU assets under operating leases on the Company's condensed consolidated balance sheets and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make operating lease payments is included in "Lease liabilities" and "Lease liabilities, net of current portion" on the Company's condensed consolidated balance sheets. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company had $9.3 million and $10.1 million of right-of-use assets as of March 31, 2021 and December 31, 2020, respectively. Operating lease liabilities were $13.7 million and $15.0 million as of March 31, 2021 and December 31, 2020, respectively. During the three ended March 31, 2021 and 2020, respectively, the Company recorded $1.8 million and $1.5 million of operating lease amortization that was charged to expense, of which $0.2 million and $0.3 million was recorded to cost of products sold. Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company has certain contracts for real estate and marketing which may contain lease and non-lease components which it has elected to treat as a single lease component. Information related to the Company's right-of-use assets and related lease liabilities were as follows: Three Months Ended March 31, 2021 2020 Cash paid for operating lease liabilities, in thousands $1,185 $1,893 Right-of-use assets obtained in exchange for new operating lease obligations, in thousands $— $— Weighted-average remaining lease term 2.7 3.2 Weighted-average discount rate 18.0% 18.0% Financing Leases The Company has financing leases primarily for laboratory and computer equipment. Assets purchased under financing leases are included in "Right-of-use assets under financing leases, net" on the condensed consolidated balance sheets. For financing leases, the associated assets are depreciated or amortized over the shorter of the relevant useful life of each asset or the lease term. Accumulated amortization of assets under financing leases totaled $5.3 million and $4.6 million as of March 31, 2021 and December 31, 2020, respectively. Maturities of Financing and Operating Leases Maturities of lease liabilities as of March 31, 2021 were as follows: Years ending December 31: (In thousands) Financing Operating Total Leases 2021 (Remaining Nine Months) $ 3,491 $ 5,644 $ 9,135 2022 — 7,655 7,655 2023 — 3,320 3,320 2024 — 150 150 2025 — — — Total lease payments 3,491 16,769 20,260 Less: amount representing interest (233) (3,050) (3,283) Total lease liability $ 3,258 $ 13,719 $ 16,977 Current lease liability $ 3,258 $ 5,510 $ 8,768 Noncurrent lease liability — 8,209 8,209 Total lease liability $ 3,258 $ 13,719 $ 16,977 Other Assets (In thousands) March 31, 2021 December 31, 2020 Equity-method investment $ 3,431 $ 2,380 Deposits 126 128 Other 1,213 1,196 Total other assets $ 4,770 $ 3,704 Accrued and Other Current Liabilities (In thousands) March 31, 2021 December 31, 2020 Payroll and related expenses $ 10,540 $ 8,230 Accrued interest 7,721 9,327 Contract termination fees 5,311 5,344 Asset retirement obligation (1) 3,003 3,041 Professional services 1,604 994 Ginkgo partnership payments obligation 878 878 Tax-related liabilities 639 656 Other 2,425 2,237 Total accrued and other current liabilities $ 32,121 $ 30,707 ______________ (1) The asset retirement obligation represents liabilities incurred but not yet discharged in connection with our 2013 abandonment of a partially constructed facility in Pradópolis, Brazil. Other noncurrent liabilities (In thousands) March 31, 2021 December 31, 2020 Liability for unrecognized tax benefit $ 7,551 $ 7,496 Ginkgo partnership payments obligation, net of current portion 7,461 7,277 Liability in connection with acquisition of equity-method investment 7,216 6,771 Contract liabilities, net of current portion 111 111 Other 128 1,099 Total other noncurrent liabilities $ 22,467 $ 22,754 |
Fair Value Measurement
Fair Value Measurement | 3 Months Ended |
Mar. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurement | Fair Value Measurement Liabilities Measured and Recorded at Fair Value on a Recurring Basis The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy: (In thousands) March 31, 2021 December 31, 2020 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liabilities Foris Convertible Note (LSA Amendment) $ — $ — $ 379,439 $ 379,439 $ — $ — $ 123,164 $ 123,164 Senior Convertible Notes — — 54,757 54,757 — — 53,387 53,387 Embedded derivatives bifurcated from debt instruments — — 188 188 — — 247 247 Freestanding derivative instruments issued in connection with other debt and equity instruments — — 31,196 31,196 — — 8,451 8,451 Total liabilities measured and recorded at fair value $ — $ — $ 465,580 $ 465,580 $ — $ — $ 185,249 $ 185,249 The Company did not hold any financial assets to be measured and recorded at fair value on a recurring basis as of March 31, 2021 and December 31, 2020. Also, there were no transfers between the levels during the three months ended March 31, 2021 or the year ended December 31, 2020. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgements and consider factors specific to the asset or liability. The method of determining the fair value of embedded derivative liabilities is described subsequently in this note. Market risk associated with embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates. Changes in fair value of derivative liabilities are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of derivative instruments". Changes in the fair value of debt that is accounted for at fair value are presented as gains or losses in the condensed consolidated statements of operations in the line captioned "Gain (loss) from change in fair value of debt". Fair Value of Debt — Foris Convertible Note At March 31, 2021, the contractual outstanding principal of the Foris Convertible Note was $50.0 million, and fair value was $379.4 million. The Company remeasured the fair value of the Foris Convertible Note under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $19.10 stock price, (ii) 10% discount yield, (iii) 0.09% risk free interest rate (iv) 45% equity volatility and (v) 5% probability of change in control. The Company assumed that if a change of control event were to occur, it would occur at the end of the calendar year. The Company recorded a loss of $256.3 million related to change in fair value of the Foris Convertible Note for the three months ended March 31, 2021. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.00 conversion price. Fair Value of Debt — Senior Convertible Notes At March 31, 2021, the contractual outstanding principal of the Senior Convertible Notes was $10.0 million, and fair value was $54.8 million. The Company measured the fair value at March 31, 2021 under a binomial lattice model (which is discussed in further detail below) using the following inputs: (i) $19.10 stock price, (ii) 210% discount yield, (iii) 0.02% risk free interest rate (iv) 45% equity volatility, and (v) 0% probability of change in control. The most sensitive input to the valuation model is the Company’s stock price in relation to the $3.50 conversion price. For the three months ended March 31, 2021, the Company recorded a $70.5 million loss from change in fair value of debt in connection with fair value remeasurement of the Senior Convertible Notes, as follows: In thousands Fair value at December 31, 2020 $ 53,387 Loss from change in fair value 70,510 Less: principal converted into common stock (20,000) Less: fair value adjustment extinguished upon conversion of debt principal (49,140) Fair value at March 31, 2021 $ 54,757 Binomial Lattice Model A binomial lattice model was used to determine whether the Foris Convertible Note and the Senior Convertible Notes (Debt Instruments) would be converted, called or held at each decision point. Within the lattice model, the following assumptions are made: (i) the convertible note will be converted early if the conversion value is greater than the holding value and (ii) the convertible note will be called if the holding value is greater than both (a) redemption price and (b) the conversion value at the time. If the convertible note is called, the holder will maximize their value by finding the optimal decision between (1) redeeming at the redemption price and (2) converting the convertible note. Using this lattice method, the Company valued the Debt Instruments using the "with-and-without method", where the fair value of the Debt Instruments including the embedded and freestanding features is defined as the "with," and the fair value of the Debt Instruments excluding the embedded and freestanding features is defined as the "without." This method estimates the fair value of the Debt Instruments by looking at the difference in the values of the Debt Instruments with the embedded and freestanding derivatives and the fair value of the Debt Instruments without the embedded and freestanding features. The lattice model uses the stock price, conversion price, maturity date, risk-free interest rate, estimated stock volatility, estimated credit spread and other instrument-specific assumptions. The Company remeasures the fair value of the Debt Instruments and records the change as a gain or loss from change in fair value of debt in the statement of operations for each reporting period. Derivative Liabilities Recognized in Connection with the Issuance of Debt Instruments The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3): (In thousands) Derivative Liability Balance at December 31, 2020 $ 8,698 Change in fair value of derivative instruments 22,745 Derecognition on settlement or extinguishment (59) Balance at March 31, 2021 $ 31,384 Freestanding Derivative Instruments On February 28, 2020, the Company entered into forbearance agreements with certain affiliates of the Schottenfeld Group LLC (the Lenders) related to certain defaults under the Schottenfeld Notes. In connection with entering into the forbearance agreements, the Company committed to issuing warrants (Warrants) to the Lenders under certain contingent events for 1.9 million shares of common stock at a $2.87 purchase price and a two-year term. The contingent obligation to issue the Warrants did not meet the derivative scope exception or equity classification criteria and was accounted for as a derivative liability and remeasured each reporting period until settled or extinguished with subsequent changes in fair value recorded through the statement of operations. The fair value of the Warrants derivative liability was determined using a Black-Scholes-Merton option pricing model based on the input assumptions for liability classified warrants table in the valuation methodology section below. At March 31, 2021, the fair value of the contingently issuable Warrants derivative liability was $31.2 million, and for the three months ended March 31, 2021, the Company recorded a $22.7 million loss on change in fair value of derivative instruments. Valuation Methodology and Approach to Measuring the Derivative Liabilities Substantially all the outstanding liabilities associated with the Company’s derivatives at March 31, 2021 and December 31, 2020 represent the fair value of freestanding equity instruments. See Note 4, "Debt", and Note 6, "Stockholders' Deficit" for further information regarding these host instruments. There is no current observable market for these types of derivatives and, as such, the Company determined the fair value of the freestanding instruments using the Black-Scholes-Merton option pricing model, which is discussed in more detail below. The Company used the Black-Scholes-Merton option pricing model to determine the fair value of its liability classified warrants as of March 31, 2021 and December 31, 2020. Input assumptions for these freestanding instruments are as follows: Range for the Period Input assumptions for liability classified warrants: March 31, 2021 December 31, 2020 Fair value of common stock on issue date $19.10 – $19.10 $2.56 – $6.18 Exercise price of warrants $2.87 – $2.87 $2.87 – $3.25 Expected volatility 114% – 114% 94% – 117% Risk-free interest rate 0.16% – 0.16% 0.13% – 1.58% Expected term in years 2 – 2 1 – 2 Dividend yield 0.0 % 0.0 % Changes in valuation assumptions can have a significant impact on the valuation of the freestanding derivative liabilities and debt that the Company elects to account for at fair value. For example, all other things being equal, generally, an increase in the Company’s stock price, change of control probability, risk-adjusted yields term to maturity/conversion or stock price volatility increases the value of the derivative liability. Assets and Liabilities Recorded at Carrying Value Financial Assets and Liabilities The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and other current accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable and credit facilities are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of these instruments using observable market-based inputs (Level 2). The carrying amount (the total amount of net debt presented on the balance sheet) of the Company's debt at March 31, 2021 and at December 31, 2020, excluding the debt instruments recorded at fair value, was $49.3 million and $86.5 million, respectively. The fair value of such debt at March 31, 2021 and at December 31, 2020 was $51.1 million and $83.3 million, respectively, and was determined by (i) discounting expected cash flows using current market discount rates estimated for certain of the debt instruments and (ii) using third-party fair value estimates for the remaining debt instruments. |
Debt
Debt | 3 Months Ended |
Mar. 31, 2021 | |
Debt Disclosure [Abstract] | |
Debt | Debt Net carrying amounts of debt are as follows: March 31, 2021 December 31, 2020 (In thousands) Principal Unaccreted Debt Discount Change in Fair Value Net Principal Unaccreted Debt Discount Change in Fair Value Net Convertible notes payable Senior convertible notes $ 10,020 $ — $ 44,737 $ 54,757 $ 30,020 $ — $ 23,367 $ 53,387 Related party convertible notes payable Foris convertible note 50,041 — 329,398 379,439 50,041 — 73,123 123,164 Loans payable and credit facilities Schottenfeld notes — — — — 12,500 (240) — 12,260 Nikko notes 2,737 (725) — 2,012 2,802 (759) — 2,043 Ginkgo note 12,000 — — 12,000 12,000 — — 12,000 Other loans payable 1,009 — — 1,009 1,227 — — 1,227 15,746 (725) — 15,021 28,529 (999) — 27,530 Related party loans payable Foris note 5,000 — — 5,000 5,000 — — 5,000 DSM notes 10,000 (4,254) — 5,746 33,000 (2,443) — 30,557 Naxyris note 23,914 (412) — 23,502 23,914 (493) — 23,421 38,914 (4,666) — 34,248 61,914 (2,936) — 58,978 Total debt $ 114,721 $ (5,391) $ 374,135 483,465 $ 170,504 $ (3,935) $ 96,490 263,059 Less: current portion (55,904) (77,437) Long-term debt, net of current portion $ 427,561 $ 185,622 Senior Convertible Notes Conversion On February 4, 2021, the Company received a notice of conversion from HT Investments MA, LLC (HT) with respect to $20.0 million of its outstanding Senior Convertible Notes, pursuant to which the Company was required to issue 5.7 million shares of common stock per the conversion price stated in the agreement and cancelled the outstanding Note. Also, under the terms of the Senior Convertible Note, HT was required to return 2.6 million shares of common stock outstanding under the Pre-Delivery Shares provision once the Company had fully repaid the principal balance. HT fulfilled its obligation to return these shares in accordance with the contractual requirement, and as a result the Company net settled the $20 million principal conversion by issuing 3.1 million of incremental shares to HT. Upon conversion of the HT Senior Convertible Note, the Company recorded a $31.9 million loss upon extinguishment of debt, which was primarily comprised of a fair value adjustment upon repayment of the note's principal. See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the Senior Convertible Notes. Schottenfeld Note Exchange On March 1, 2021, the Company entered into an Exchange and Settlement Agreement (Exchange Agreement) with Schottenfeld Opportunities Fund II, L.P. and certain other holders of notes under the Credit and Security Agreement dated November 14, 2019 (Schottenfeld Notes). Pursuant to the terms of the Exchange Agreement, the Company paid all accrued and unpaid interest on the $12.5 million principal balance outstanding under the Schottenfeld Notes, and issued 4.1 million net shares of common stock in a cashless exchange and cancellation of all amounts due and outstanding under the Notes and related loan documents and all warrants held by each of the holders of Schottenfeld Notes. Upon conversion of the Schottenfeld note balance, the Company recorded a $28.9 million loss upon extinguishment of debt, which primarily represented the fair value of common shares issued in excess of debt principal extinguished. See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the Schottenfeld Notes. DSM Notes Amendments and Repayment On December 28, 2017, the Company and DSM Finance, a wholly owned subsidiary of Koninklijke DSM N.V. (DSM), entered into a credit agreement (the DSM Credit Agreement) to make available to the Company an unsecured credit facility of $25.0 million. On December 28, 2017, the Company borrowed $25.0 million under the DSM Credit Agreement and issued a promissory note to DSM Finance. The $25 million Note matures on December 31, 2021 and accrues interest at 10% per annum, payable quarterly. On September 17, 2019, the Company and DSM entered into a credit agreement (the 2019 DSM Credit Agreement) to make available to the Company a secured credit facility in an aggregate principal amount of $8.0 million. In September 2019, the Company borrowed the $8.0 million in three installments. The promissory notes issued under the 2019 DSM Credit Agreement (i) mature on August 7, 2022, (ii) accrue interest at a rate of 12.5% per annum, payable quarterly and (iii) are secured by a first-priority lien on certain Company intellectual property licensed to DSM. In March 2021, the Company entered into amendments (the March 2021 Amendments) to the $25 million Note and the $8 million Note that provided for (i) the prepayment of the $8 million Note, (ii) a $15 million partial prepayment of the $25 million Note and (iii) extension of the maturity date from December 31, 2021 to April 15, 2022 for the remaining $10 million principal balance under the $25 million Note, in exchange for a $2.5 million prepayment fee The Company repaid $23 million on March 31, 2021 to extinguish the $8 million Note and to partially repay the $25 million Note. The Company evaluated the March 2021 Amendments, and concluded the before and after cash flows resulting from the amendments were not significantly different and accounted for the amendments to the Notes as a debt modification. Consequently, the $2.5 million Prepayment Fee was recorded as an incremental debt discount to the remaining $10 million principal balance under the $25 million Note. The Company will accrete the adjusted discount over the Note’s amended remaining term using the effective interest method. See the Company's 2020 Form 10-K, Note 4, “Debt” for additional information regarding the DSM notes. Future Minimum Payments Future minimum payments under the Company's debt agreements as of March 31, 2021 are as follows: (In thousands) Convertible Notes Loans Related Party Convertible Notes Related Party Loans Payable and Credit Facilities Total 2021 (Remaining Nine Months) $ 11,189 $ 2,260 $ — $ 2,782 $ 16,231 2022 — 13,268 59,578 42,379 115,225 2023 — 399 — — 399 2024 — 398 — — 398 2025 — 397 — — 397 Thereafter — 1,473 — — 1,473 Total future minimum payments 11,189 18,195 59,578 45,161 134,123 Less: amount representing interest (1,169) (2,449) (9,537) (6,247) (19,402) Present value of minimum debt payments 10,020 15,746 50,041 38,914 114,721 Less: current portion of debt principal (10,020) (1,280) — — (11,300) Noncurrent portion of debt principal $ — $ 14,466 $ 50,041 $ 38,914 $ 103,421 |
Mezzanine Equity
Mezzanine Equity | 3 Months Ended |
Mar. 31, 2021 | |
Temporary Equity Disclosure [Abstract] | |
Mezzanine Equity | Mezzanine EquityMezzanine equity at March 31, 2021 and December 31, 2020 is comprised of proceeds from shares of common stock sold on May 10, 2016 to the Bill & Melinda Gates Foundation (the Gates Foundation). In connection with the stock sale, the Company and the Gates Foundation entered into an agreement under which the Company agreed to expend an aggregate amount not less than the proceeds from the stock sale to develop a yeast strain that produces artemisinic acid and/or amorphadiene at a low cost and to supply such artemisinic acid and amorphadiene to companies qualified to convert artemisinic acid and amorphadiene to artemisinin for inclusion in artemisinin combination therapies used to treat malaria. If the Company defaults in its obligation to use the proceeds from the stock sale as set forth above or defaults under certain other commitments in the agreement, the Gates Foundation will have the right to request that the Company redeem, or facilitate the purchase by a third party, the shares then held by the Gates Foundation at a price per share equal to the greater of (i) the closing price of the Company’s common stock on the trading day prior to the redemption or purchase, as applicable, or (ii) an amount equal to $17.10 plus a compounded annual return of 10%. As of March 31, 2021, the Company's remaining research and development obligation under this arrangement was $0.3 million. |
Stockholders' Deficit
Stockholders' Deficit | 3 Months Ended |
Mar. 31, 2021 | |
Equity [Abstract] | |
Stockholders' Deficit | Stockholders' Deficit Warrants and Rights Activity Summary In connection with various debt and equity transactions (see Note 4, “Debt” above and Note 4, "Debt" and Note 6, “Stockholders’ Deficit” in Part II, Item 8 of the 2020 Form 10-K), the Company has issued warrants exercisable for shares of common stock. The following table summarizes warrants outstanding at March 31, 2021: Transaction Number Outstanding as of March 31, 2021 Exercise Price per Share as of March 31, 2021 Blackwell and Silverback warrants 1,000,000 $ 3.25 January 2020 warrant exercise right shares 4,209,608 $ 2.87 April 2019 PIPE warrants 1,381,940 $4.76/$5.02 Naxyris LSA warrants 2,000,000 $ 2.87 October 2019 Naxyris warrant 2,000,000 $ 3.87 May 2019 6.50% Note Exchange warrants 960,225 $ 2.87 May 2017 cash warrants 1,863,056 $ 2.87 May 2017 dilution warrants 3,085,893 $ 0.00 August 2017 dilution warrants 3,028,983 $ 0.00 July 2015 related party debt exchange 58,690 $ 0.15 Other 1,406 $ 160.05 19,589,801 Warrant Exercises During the three months ended March 31, 2021, warrant-holders exercised warrants to purchase approximately 24.8 million shares of the Company’s common stock at a weighted-average exercise price of $3.06 per share, for net proceeds to the Company of $32.2 million. Some of the exercises were cashless or in connection with the Schottenfeld Note Exchange, which resulted in fewer shares being issued than the number of warrant-shares exercised. As a result, 21.6 million shares were issued. |
Net Loss Per Share Attributable
Net Loss Per Share Attributable to Common Shareholders | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share Attributable to Common Shareholders | Net Loss per Share Attributable to Common Stockholders For the three months ended March 31, 2021 and 2020, basic loss per share was the same as diluted loss per share, because the inclusion of all potentially dilutive securities outstanding was antidilutive. The Company follows the two-class method when computing net loss per common share when shares are issued that meet the definition of participating securities. The two-class method requires income available to common stockholders for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The two-class method also requires losses for the period to be allocated between common stock and participating securities based on their respective rights if the participating security contractually participates in losses. The Company’s convertible preferred stock are participating securities as they contractually entitle the holders of such shares to participate in dividends and contractually require the holders of such shares to participate in the Company’s losses. The following table presents the calculation of basic and diluted loss per share: Three Months Ended March 31, (In thousands, except shares and per share amounts) 2021 2020 Numerator: Net loss attributable to Amyris, Inc. $ (291,251) $ (87,844) Less: losses allocated to participating securities 2,099 1,087 Net loss attributable to Amyris, Inc. common stockholders, basic and diluted $ (289,152) $ (86,757) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 267,733,555 155,065,635 Loss per share, basic and diluted $ (1.08) $ (0.56) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive: Three Months Ended March 31, 2021 2020 Period-end common stock warrants 13,416,235 50,518,519 Convertible promissory notes (1) 19,540,447 9,217,185 Period-end stock options to purchase common stock 6,205,576 5,578,264 Period-end restricted stock units 6,653,640 5,298,639 Period-end preferred stock 1,943,661 1,943,661 Total potentially dilutive securities excluded from computation of diluted loss per share 47,759,559 72,556,268 ______________ (1) The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Guarantor Arrangements The Company has agreements whereby it indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is serving in his or her official capacity. The indemnification period remains enforceable for the executive officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of March 31, 2021 and December 31, 2020. The Foris Convertible Note (see Note 4, "Debt") is collateralized by first-priority liens on substantially all of the Company's assets, including Company intellectual property, other than certain Company intellectual property licensed to DSM and the Company's shares of Aprinnova. Certain of the Company’s subsidiaries have guaranteed the Company’s obligations under the Foris Convertible Note. The obligations of the Company under the Naxyris Note (see Note 4, "Debt") are (i) guaranteed by the Subsidiary Guarantors and (ii) secured by a perfected security interest in substantially all of the assets of the Company and the Subsidiary Guarantors (the Collateral), junior in payment priority to Foris subject to certain limitations and exceptions, as well as the terms of the Intercreditor Agreement. The Nikko $3.9 million note is collateralized by a first-priority lien on 10.0% of the Aprinnova JV interests owned by the Company. Other Matters Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but will only be recorded when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgement. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be reasonably estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed. On April 3, 2019, a securities class action complaint was filed against Amyris and our CEO, John G. Melo, and former CFO, Kathleen Valiasek, in the U.S. District Court for the Northern District of California. The complaint seeks unspecified damages on behalf of a purported class that would comprise all persons and entities that purchased or otherwise acquired our securities between March 15, 2018 and March 19, 2019. The complaint, which was amended by the lead plaintiff on September 13, 2019, alleges securities law violations based on statements and omissions made by the Company during such period. On October 25, 2019, the defendants filed a motion to dismiss the securities class action complaint, which was denied by the court on October 5, 2020. The Company filed its answer to the securities class action complaint on October 26, 2020. Subsequent to the filing of the securities class action complaint described above, on June 21, 2019 and October 1, 2019, respectively, two separate purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California (Bonner v. Doerr, et al., and Carlson v. Doerr, et al.) based on similar allegations to those made in the securities class action complaint and naming the Company, and certain of the Company’s current and former officers and directors, as defendants. The derivative lawsuits sought to recover, on the Company’s behalf, unspecified damages purportedly sustained by the Company in connection with allegedly misleading statements and omissions made in connection with the Company’s securities filings. The derivative lawsuits were dismissed on October 18, 2019 (Bonner) and December 10, 2019 (Carlson), without prejudice. On November 3, 2020, Bonner re-filed its derivative complaint against the Company in San Mateo County Superior Court. The Company filed its demurrer to the complaint on January 13, 2021 and attended a preliminary hearing on April 22, 2021. An additional shareholder derivative complaint (Kimbrough v. Melo, et al.), substantially identical to the Bonner complaint, was filed on December 18, 2020 in the United States District Court for the Northern District of California. On February 19, 2021, the Company filed its motion to dismiss the Kimbrough complaint. In response, the Kimbrough complaint was dismissed in federal court on March 4, 2021 and refiled in state court on March 12, 2021. By agreement, the Kimbrough and Bonner complaints were consolidated for all purposes on April 9, 2021. By May 10, 2021, the derivative shareholder plaintiffs will either file a new complaint or designate one of the existing complaints as operative. A briefing schedule on a demurrer to that complaint will be negotiated no later than May 24, 2021. The Company believes the securities class action and derivative complaints lack merit, and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result from these matters. On September 10, 2020, LAVVAN, Inc. (Lavvan) filed a suit against the Company in the United States District Court for the Southern District of New York alleging breach of contract, patent infringement, and trade secret misappropriation in connection with that certain Research, Collaboration and License Agreement between Lavvan and Amyris, dated March 18, 2019, as amended (Cannabinoid Agreement). Amyris filed motions to compel arbitration or to dismiss on October 2, 2020. On October 30, Lavvan filed its opposition to the motions and the Company filed its reply to such opposition on November 13, 2020. The matter is fully briefed and the parties are awaiting an order from the Court. The Company believes the suit lacks merit and intends to continue to defend itself vigorously. Given the early stage of these proceedings, it is not yet possible to reliably determine any potential liability that could result therefrom. The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not resulted in legal proceedings or have not been fully adjudicated. Such matters that may arise in the ordinary course of business are subject to many uncertainties and outcomes, and are not predictable with reasonable assurance; therefore, an estimate of all the reasonably possible losses cannot be determined at this time. If one or more of these legal disputes or claims resulted in settlements or legal proceedings that were resolved against the Company for amounts in excess of management’s |
Revenue Recognition and Contrac
Revenue Recognition and Contract Assets and Liabilities | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Revenue Recognition and Contract Assets and Liabilities | Revenue Recognition and Contract Assets and Liabilities Disaggregation of Revenue The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer: Three Months Ended March 31, (In thousands) 2021 2020 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total United States $ 20,090 $ — $ 250 $ 20,340 $ 11,944 $ — $ — $ 11,944 Europe 2,972 143,800 2,346 149,118 3,242 5,161 3,356 11,759 Asia 4,405 2,284 6,689 2,018 — 2,759 4,777 Brazil 313 313 577 — — 577 Other 399 399 73 — — 73 $ 28,179 $ 143,800 $ 4,880 $ 176,859 $ 17,854 $ 5,161 $ 6,115 $ 29,130 The following table presents revenue by major product and service, as well as by customer type: Three Months Ended March 31, (In thousands) 2021 2020 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total Consumer $ 15,653 $ — $ — $ 15,653 $ 9,065 $ — $ — $ 9,065 Ingredients 12,526 143,800 — 156,326 8,789 5,161 — 13,950 Research and development — — 4,880 4,880 — — 6,115 6,115 $ 28,179 $ 143,800 $ 4,880 $ 176,859 $ 17,854 $ 5,161 $ 6,115 $ 29,130 Revenue from Significant Revenue Agreements In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2020 Form 10-K), the Company recognized the following revenue for the three months ended March 31, 2021 and 2020 : Three Months Ended March 31, (In thousands) 2021 2020 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total DSM - related party $ 1,662 $ 143,612 $ 2,000 $ 147,274 $ 49 $ 3,750 $ 3,018 $ 6,817 Sephora 4,441 — — 4,441 4,446 — — 4,446 Yifan — — 2,284 2,284 — — 2,709 2,709 Firmenich 379 188 205 772 1,229 1,411 161 2,801 Givaudan 210 — — 210 2,109 — — 2,109 Subtotal revenue from significant revenue agreements 6,692 143,800 4,489 154,981 7,833 5,161 5,888 18,882 Revenue from all other customers 21,487 — 391 21,878 10,021 — 227 10,248 Total revenue from all customers $ 28,179 $ 143,800 $ 4,880 $ 176,859 $ 17,854 $ 5,161 $ 6,115 $ 29,130 DSM License Agreement and Contract Assignment On March 31, 2021, the Company and DSM entered into a license agreement and asset purchase agreement pursuant to which DSM acquired exclusive rights to the Company’s Flavor and Fragrance (F&F) product portfolio. The Company granted DSM exclusive licenses covering specific intellectual property (F&F Intellectual Property License) of the Company and assigned the Company’s rights and obligations under certain F&F ingredients supply agreements to DSM, in exchange for non-refundable upfront consideration totaling $150 million, and up to $235 million of contingent consideration if and when certain commercial milestones are achieved in each of the calendar years 2022 through 2024. DSM also acquired the Company’s F&F finished goods inventory on-hand, unbilled accounts receivables and billed accounts receivable that were uncollected at closing. The Company and DSM also entered into a 15-year manufacturing agreement whereby the Company will manufacture certain F&F ingredients for DSM to supply to third parties. The Company determined the licenses to be functional intellectual property licenses allowing DSM the immediate use of and benefit from the technology, and concluded the licenses and related assigned F&F ingredients supply agreements, the asset purchase agreement and the manufacturing agreement were revenue contracts within the scope of ASC 606. The Company identified three distinct performance obligations: (i) F&F license, (ii) finished goods inventory and (iii) receivables, that once delivered are satisfied at a point in time. The Company also concluded the additional contingent consideration and manufacturing supply agreement represent variable consideration that will be fully constrained until the commercial targets are probable of achievement and the products are manufactured and sold. The Company allocated the $150 million transaction price to the three revenue performance obligations using the residual approach. The transaction price was first allocated to the transferred inventory and receivables at the stand-alone selling price for these performance obligations, and the residual consideration was allocated to the F&F intellectual property licenses: • Finished goods inventory - $1.5 million • Receivables - $4.9 million • F&F intellectual property licenses - $143.6 million The Company also concluded the F&F intellectual property licenses and the assigned F&F supply agreements had been fully delivered with no further performance obligation upon closing the transaction, and recognized license revenue of $143.6 million in the period ended March 31, 2021. Due to the related party nature of the transaction with DSM, who is a significant shareholder with two members on the Company’s board of directors, the Company performed a fair value assessment of the F&F intellectual property licenses under an income approach using a discounted cash flow model, in part with the assistance of a third-party valuation firm, and concluded the $143.6 million residual consideration received in exchange for the F&F intellectual property licenses approximated the fair value and stand-alone selling price of the F&F intellectual property licenses. DSM Performance Agreement In December 2017, the Company and DSM entered into a research and development services agreement (Performance Agreement), pursuant to which the Company would provide services to DSM relating to the further development of the technology underlying farnesene-related products in exchange for certain bonus payments in the event that specific performance metrics were achieved. If the Company did not meet the established metrics under the Performance Agreement, the Company would be required to pay $1.9 million to DSM. The Company accounted for the Performance Agreement under ASC 606 as a combined transaction with the Farnesene license granted to DSM in connection with the sale of the Brotas facility in December 2017. The Performance Agreement was allocated $1.2 million of the transaction price under a relative fair value allocation approach, and was recorded as a contract asset reflecting the Company’s right to receive additional consideration and deferred revenue reflecting the probability of returning to DSM a portion of the cash received under the combined transaction. In the first quarter of 2021, the Company and DSM determined the performance metrics would not be reasonably achieved without the Company providing further research and development services and concluded the Performance Agreement and related activities should be terminated. As a result, the Company paid DSM $1.9 million and reduced the deferred revenue liability, and expensed the contract asset balance and recorded $1.9 million of additional research and development expense during the three months ended March 31, 2021. DSM Ingredients Collaboration Pursuant to the September 2017 research and development collaboration agreement, as amended, the Company provides DSM with research and development services for specific field of use ingredients. The Company concluded the amended agreement contained a single performance obligation to provide research and development services delivered over time and that revenue recognition is based on an input measure of progress as labor hours are expended each quarter. DSM funds the development work with payments of $2.0 million quarterly from October 1, 2020 to September 30, 2021 for services singularly focused on achieving a certain fermentation yield and cost target over the twelve-month period. During the three months ended March 31, 2021 and 2020, the Company recognized $2.0 million and $3.0 million of collaboration revenue in connection with the amended agreement. Yifan Collaborations The Company has a collaboration agreement with Yifan Pharmaceutical Co., Ltd. (Yifan), a leading Chinese pharmaceutical company. During the three months ended March 31, 2021 and 2020, the Company recognized $2.3 million and $2.7 million of collaboration revenue, and $16.6 million of cumulative-to-date collaboration revenue in connection with the agreement. At March 31, 2021, the Company also recorded a $5.9 million contract asset in connection with the Collaboration Agreement. For more information about the DSM ingredients collaboration and Yifan collaboration, see the Company's 2020 Form 10-K, Part II, Item 8, Note 10, "Revenue Recognition". Contract Assets and Liabilities When a contract results i n revenue being recognized in excess of the amount the Company has invoiced or has the right to invoice to the customer, a contract asset is recognized. Contract assets are transferred to accounts receivable, net when the rights to the consideration become unconditional. Contract liabilities consist of payments received from customers, or such consideration that is contractually due, in advance of providing the product or performing services such that control has not passed to the customer. Trade receivables related to revenue from contracts with customers are included in accounts receivable on the condensed consolidated balance sheets, net of the allowance for doubtful accounts. Trade receivables are recorded for the sale of goods or the performance of services at the point of renewable product sale or in accordance with the contractual payment terms for licenses and royalties, and grants and collaborative research and development services for the amount payable by the customer to the Company. Contract Balances The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers: (In thousands) March 31, 2021 December 31, 2020 Accounts receivable, net $ 27,036 $ 32,846 Accounts receivable - related party, net $ 391 $ 12,110 Contract assets $ 6,589 $ 4,178 Contract assets - related party $ 2,000 $ 1,203 Contract liabilities $ 6,163 $ 4,468 Contract liabilities, noncurrent (1) $ 111 $ 111 (1) As of March 31, 2021 and December 31, 2020, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets. Remaining Performance Obligations The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2021. (In thousands) As of March 31, 2021 Remaining 2021 $ 143 2022 3,103 2023 1,430 2024 and thereafter 429 Total from all customers $ 5,105 In accordance with the disclosure provisions of ASC 606, the table above excludes estimated future revenues for performance obligations that are part of a contract that has an original expected duration of one year or less or a performance obligation with variable consideration that is recognized using the sales-based royalty exception for licenses of intellectual |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Related Party Transactions Related Party Debt See Note 4, "Debt," for details of the DSM Notes Amendments and Repayments that occurred during the three months ended March 31, 2021. Related party debt was as follows: March 31, 2021 December 31, 2020 In thousands Principal Unaccreted Debt Discount Change in Fair Value Net Principal Unaccreted Debt Discount Change in Fair Value Net Foris notes $ 55,041 $ — $ 329,398 $ 384,439 $ 55,041 $ — $ 73,123 $ 128,164 DSM notes 10,000 (4,254) — 5,746 33,000 (2,443) — 30,557 Naxyris note 23,914 (412) — 23,502 23,914 (493) — 23,421 $ 88,955 $ (4,666) $ 329,398 $ 413,687 $ 111,955 $ (2,936) $ 73,123 $ 182,142 Related Party Revenue See Note 9, "Revenue Recognition", for information about the March 31, 2021 DSM License Agreement and Contract Assignment. Related Party Accounts Receivable, Unbilled Receivables and Accounts Payable Related party accounts receivable, contract assets and accounts payable were as follows: (In thousands) March 31, 2021 December 31, 2020 Accounts receivable - related party $ 391 $ 12,110 Contract assets - related party $ 2,000 $ 1,203 Accounts payable $ 10,302 $ 5,011 |
Stock-based Compensation
Stock-based Compensation | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Stock-based Compensation | Stock-based Compensation The Company’s stock option activity and related information for the three months ended March 31, 2021 was as follows: Quantity of Stock Options Weighted- Weighted-average Aggregate Outstanding - December 31, 2020 6,502,096 $ 7.64 7.6 $ 8,875 Granted 131,408 $ 14.52 Exercised (375,390) $ 5.12 Forfeited or expired (52,538) $ 38.21 Outstanding - March 31, 2021 6,205,576 $ 7.68 7.4 $ 82,615 Vested or expected to vest after March 31, 2021 5,697,447 $ 7.91 7.3 $ 75,493 Exercisable at March 31, 2021 1,259,029 $ 18.19 5.8 $ 12,884 The Company’s restricted stock units (RSUs) activity and related information for the three months ended March 31, 2021 was as follows: Quantity of Restricted Stock Units Weighted-average Grant-date Fair Value Weighted-average Remaining Contractual Life, in Years Outstanding - December 31, 2020 7,043,909 $ 4.18 1.5 Awarded 345,903 $ 13.53 Released (496,492) $ 4.34 Forfeited (239,680) $ 4.22 Outstanding - March 31, 2021 6,653,640 $ 4.65 1.4 Vested or expected to vest after March 31, 2021 6,082,165 $ 4.65 1.3 Stock-based compensation expense related to employee and non-employee options, RSUs and ESPP during the three months ended March 31, 2021 and 2020 is reflected in the condensed consolidated statements of operations as follows: Three Months Ended March 31, (In thousands) 2021 2020 Cost of products sold $ 63 $ — Research and development 1,062 1,065 Sales, general and administrative 3,156 2,439 Total stock-based compensation expense $ 4,281 $ 3,504 As of March 31, 2021, there was unrecognized compensation expense of $30.0 million related to stock options and RSUs. The Company expects to recognize this expense over a weighted-average period of 2.4 years. Evergreen Shares for 2020 Equity Incentive Plan and 2010 Employee Stock Purchase Plan In March 2021, the Board approved increases to the number of shares available for issuance under the Company's 2020 Equity Incentive Plan (the 2020 Equity Plan) and 2010 Employee Stock Purchase Plan (the 2010 ESPP). The increase in shares in connection with the 2020 Equity Plan represented an automatic annual increase in the number of shares available for grant and issuance under the 2020 Equity Plan of 12,247,572 shares (Evergreen Shares). This increase is equal to approximately 5.0% of the 244,951,446 total outstanding shares of the Company’s common stock as of December 31, 2020. This automatic increase was effective as of January 1, 2021. The increase in shares in connection with the 2010 ESPP represented an automatic annual increase in the number of shares reserved for issuance of 42,077 shares, which represents the remaining allowable under the existing 1,666,666 maximum limit for share issuance under the 2010 ESPP. This automatic increase was effective as of January 1, 2021. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events Primary and Secondary Offering On April 8, 2021, the Company entered into an underwriting agreement (the Underwriting Agreement) with J.P. Morgan Securities LLC and Cowen and Company, LLC (the Underwriters) and with certain stockholders of the Company (the Selling Stockholders), pursuant to which the Selling Stockholders agreed to sell 11,390,797 shares of common stock of the Company, par value $0.0001 per share and Amyris agreed to issue and sell 7,656,822, at a public offering price of $15.75 per share. DSM International B.V. and affiliates of Vivo Capital LLC were the Secondary Offering Selling Stockholders. Under the terms of the Underwriting Agreement, the Selling Stockholders and Amyris granted the Underwriters a 30-day option to purchase up to an additional 1,708,619 shares of Common Stock from the Selling Stockholders and 1,148,523 shares of Common Stock from Amyris. The Underwriters exercised this option in full. Net proceeds to the Company from the 8,805,345 new shares issued by the Company were approximately $130.7 million (inclusive of the underwriters’ option to purchase additional shares), after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company did not receive any proceeds from the sale of common stock in the secondary offering by the Selling Stockholders. Ingredion Agreement On May 3, 2021, the Company and Ingredion Incorporated entered into a Membership Interest Purchase Agreement (MIPA) under which (i) the Company will assign and transfer certain contracts for the sale and distribution of RebM to Ingredion’s subsidiary, PureCircle, which will become the exclusive global business-to-business commercialization partner for the Company’s sugar reduction technology that includes fermented RebM; (ii) the Company and Ingredion will enter into certain intellectual property license agreements to make, have made, commercialize and advance the development of sustainably sourced, zero-calorie, nature-based sweeteners and potentially other types of fermentation-based ingredients; (iii) Ingredion will purchase 31% of all of the membership interests in Amyris RealSweet LLC, a wholly owned subsidiary of the Company incorporated on April 15, 2021 (RealSweet), which entity will own the new manufacturing facility under construction in Brazil, and; (iv) The parties will enter into an R&D collaboration agreement to create and advance the development of sustainably sourced, zero-calorie, nature-based sweeteners, and potentially other types of fermentation-based food ingredients. The Company will continue to own and market its Purecane™ consumer brand offering of tabletop and culinary sweetener products to consumers. Under the terms of the license agreement, the Company will receive an upfront $10 million license fee at closing and additional milestone payments in the aggregate of $35 million upon achievement of certain manufacturing cost targets and RebM sales revenue. The Company will also receive $30 million of cash and non-cash consideration from Ingredion in exchange for their 31% interest in RealSweet. Additionally, the Company will earn a profit share from future Reb M sales by PureCircle. The closing of the MIPA is subject to customary closing conditions. |
Basis of Presentation and Sum_2
Basis of Presentation and Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of accounting | The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying interim condensed consolidated financial statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. |
Use of Estimates and Judgements | Use of Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgements and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements. Significant estimates and judgements used in these consolidated financial statements are discussed in the relevant |
Accounting Standards or Updates Recently Adopted and Accounting Standards or Updates Not Yet Effective | Accounting Standards or Updates Recently Adopted In the three months ended March 31, 2021, the Company adopted these accounting standards or updates: Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) . The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 202 1. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements. Equity Securities, Equity-method Investments and Certain Derivative s In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 . The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements. Accounting Standards or Updates Not Yet Adopted Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments . ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. Entities will now use forward-looking information to better form their credit loss estimates. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an entity's portfolio. ASU 2016-13 will be effective for the Company in the first quarter of 2023. The Company is currently evaluating the impact this standard will have on its consolidated financial statements and related disclosures. Convertible Debt, and Derivatives and Hedging In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures. |
Balance Sheet Details (Tables)
Balance Sheet Details (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Allowance for Doubtful Accounts | Allowance for Doubtful Accounts (In thousands) Balance at Beginning of Year Provisions Write-offs, Net Balance at End of Period Three months ended March 31, 2021 $ 137 $ 17 $ — $ 154 Three months ended March 31, 2020 $ 45 $ — $ — $ 45 |
Inventories | Inventories (In thousands) March 31, 2021 December 31, 2020 Raw materials $ 12,185 $ 11,800 Work-in-process 8,702 10,760 Finished goods 26,752 20,302 Inventories $ 47,639 $ 42,862 |
Deferred Cost of Products Sold | Deferred cost of products sold - related party (In thousands) March 31, 2021 December 31, 2020 Deferred cost of products sold - related party $ 5,220 $ 9,801 Deferred cost of products sold, noncurrent - related party 9,391 9,939 Total $ 14,611 $ 19,740 |
Prepaid Expenses and Other Current Assets | Prepaid expenses and other current assets (In thousands) March 31, 2021 December 31, 2020 Prepayments, advances and deposits $ 13,453 $ 6,637 Non-inventory production supplies 3,364 3,989 Recoverable taxes from Brazilian government entities 1,020 1,063 Other 1,409 1,414 Total prepaid expenses and other current assets $ 19,246 $ 13,103 |
Property, Plant and Equipment, Net | Property, Plant and Equipment, Net (In thousands) March 31, 2021 December 31, 2020 Machinery and equipment $ 49,880 $ 50,415 Leasehold improvements 44,800 45,197 Computers and software 7,362 6,741 Furniture and office equipment, vehicles and land 3,450 3,507 Construction in progress 7,238 7,250 112,730 113,110 Less: accumulated depreciation and amortization (80,797) (80,235) Property, plant and equipment, net $ 31,933 $ 32,875 |
Schedule Of Depreciation and Amortization | During the three months ended March 31, 2021 and 2020, depreciation and amortization expense, including amortization of right-of-use assets under financing leases, was as follows: Three Months Ended March 31, (In thousands) 2021 2020 Depreciation and amortization expense $ 2,114 $ 1,719 |
Lease, Cost | Information related to the Company's right-of-use assets and related lease liabilities were as follows: Three Months Ended March 31, 2021 2020 Cash paid for operating lease liabilities, in thousands $1,185 $1,893 Right-of-use assets obtained in exchange for new operating lease obligations, in thousands $— $— Weighted-average remaining lease term 2.7 3.2 Weighted-average discount rate 18.0% 18.0% |
Lessee, Lease Liability, Maturity | Maturities of lease liabilities as of March 31, 2021 were as follows: Years ending December 31: (In thousands) Financing Operating Total Leases 2021 (Remaining Nine Months) $ 3,491 $ 5,644 $ 9,135 2022 — 7,655 7,655 2023 — 3,320 3,320 2024 — 150 150 2025 — — — Total lease payments 3,491 16,769 20,260 Less: amount representing interest (233) (3,050) (3,283) Total lease liability $ 3,258 $ 13,719 $ 16,977 Current lease liability $ 3,258 $ 5,510 $ 8,768 Noncurrent lease liability — 8,209 8,209 Total lease liability $ 3,258 $ 13,719 $ 16,977 |
Other Assets | Other Assets (In thousands) March 31, 2021 December 31, 2020 Equity-method investment $ 3,431 $ 2,380 Deposits 126 128 Other 1,213 1,196 Total other assets $ 4,770 $ 3,704 |
Accrued and Other Current Liabilities | Accrued and Other Current Liabilities (In thousands) March 31, 2021 December 31, 2020 Payroll and related expenses $ 10,540 $ 8,230 Accrued interest 7,721 9,327 Contract termination fees 5,311 5,344 Asset retirement obligation (1) 3,003 3,041 Professional services 1,604 994 Ginkgo partnership payments obligation 878 878 Tax-related liabilities 639 656 Other 2,425 2,237 Total accrued and other current liabilities $ 32,121 $ 30,707 ______________ (1) The asset retirement obligation represents liabilities incurred but not yet discharged in connection with our 2013 abandonment of a partially constructed facility in Pradópolis, Brazil. |
Other Liabilities | Other noncurrent liabilities (In thousands) March 31, 2021 December 31, 2020 Liability for unrecognized tax benefit $ 7,551 $ 7,496 Ginkgo partnership payments obligation, net of current portion 7,461 7,277 Liability in connection with acquisition of equity-method investment 7,216 6,771 Contract liabilities, net of current portion 111 111 Other 128 1,099 Total other noncurrent liabilities $ 22,467 $ 22,754 |
Fair Value Measurement (Tables)
Fair Value Measurement (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The following tables summarize liabilities measured at fair value, and the respective fair value by input classification level within the fair value hierarchy: (In thousands) March 31, 2021 December 31, 2020 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Liabilities Foris Convertible Note (LSA Amendment) $ — $ — $ 379,439 $ 379,439 $ — $ — $ 123,164 $ 123,164 Senior Convertible Notes — — 54,757 54,757 — — 53,387 53,387 Embedded derivatives bifurcated from debt instruments — — 188 188 — — 247 247 Freestanding derivative instruments issued in connection with other debt and equity instruments — — 31,196 31,196 — — 8,451 8,451 Total liabilities measured and recorded at fair value $ — $ — $ 465,580 $ 465,580 $ — $ — $ 185,249 $ 185,249 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation | For the three months ended March 31, 2021, the Company recorded a $70.5 million loss from change in fair value of debt in connection with fair value remeasurement of the Senior Convertible Notes, as follows: In thousands Fair value at December 31, 2020 $ 53,387 Loss from change in fair value 70,510 Less: principal converted into common stock (20,000) Less: fair value adjustment extinguished upon conversion of debt principal (49,140) Fair value at March 31, 2021 $ 54,757 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation | The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt instruments, either freestanding or embedded, measured at fair value using significant unobservable inputs (Level 3): (In thousands) Derivative Liability Balance at December 31, 2020 $ 8,698 Change in fair value of derivative instruments 22,745 Derecognition on settlement or extinguishment (59) Balance at March 31, 2021 $ 31,384 |
Fair Value Measurement Inputs and Valuation Techniques | Input assumptions for these freestanding instruments are as follows: Range for the Period Input assumptions for liability classified warrants: March 31, 2021 December 31, 2020 Fair value of common stock on issue date $19.10 – $19.10 $2.56 – $6.18 Exercise price of warrants $2.87 – $2.87 $2.87 – $3.25 Expected volatility 114% – 114% 94% – 117% Risk-free interest rate 0.16% – 0.16% 0.13% – 1.58% Expected term in years 2 – 2 1 – 2 Dividend yield 0.0 % 0.0 % |
Debt (Tables)
Debt (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of Debt | Net carrying amounts of debt are as follows: March 31, 2021 December 31, 2020 (In thousands) Principal Unaccreted Debt Discount Change in Fair Value Net Principal Unaccreted Debt Discount Change in Fair Value Net Convertible notes payable Senior convertible notes $ 10,020 $ — $ 44,737 $ 54,757 $ 30,020 $ — $ 23,367 $ 53,387 Related party convertible notes payable Foris convertible note 50,041 — 329,398 379,439 50,041 — 73,123 123,164 Loans payable and credit facilities Schottenfeld notes — — — — 12,500 (240) — 12,260 Nikko notes 2,737 (725) — 2,012 2,802 (759) — 2,043 Ginkgo note 12,000 — — 12,000 12,000 — — 12,000 Other loans payable 1,009 — — 1,009 1,227 — — 1,227 15,746 (725) — 15,021 28,529 (999) — 27,530 Related party loans payable Foris note 5,000 — — 5,000 5,000 — — 5,000 DSM notes 10,000 (4,254) — 5,746 33,000 (2,443) — 30,557 Naxyris note 23,914 (412) — 23,502 23,914 (493) — 23,421 38,914 (4,666) — 34,248 61,914 (2,936) — 58,978 Total debt $ 114,721 $ (5,391) $ 374,135 483,465 $ 170,504 $ (3,935) $ 96,490 263,059 Less: current portion (55,904) (77,437) Long-term debt, net of current portion $ 427,561 $ 185,622 |
Schedule of Long-term Debt Instruments | Future minimum payments under the Company's debt agreements as of March 31, 2021 are as follows: (In thousands) Convertible Notes Loans Related Party Convertible Notes Related Party Loans Payable and Credit Facilities Total 2021 (Remaining Nine Months) $ 11,189 $ 2,260 $ — $ 2,782 $ 16,231 2022 — 13,268 59,578 42,379 115,225 2023 — 399 — — 399 2024 — 398 — — 398 2025 — 397 — — 397 Thereafter — 1,473 — — 1,473 Total future minimum payments 11,189 18,195 59,578 45,161 134,123 Less: amount representing interest (1,169) (2,449) (9,537) (6,247) (19,402) Present value of minimum debt payments 10,020 15,746 50,041 38,914 114,721 Less: current portion of debt principal (10,020) (1,280) — — (11,300) Noncurrent portion of debt principal $ — $ 14,466 $ 50,041 $ 38,914 $ 103,421 |
Stockholders' Deficit (Tables)
Stockholders' Deficit (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Equity [Abstract] | |
Schedule of Stockholders' Equity Note, Warrants or Rights | The following table summarizes warrants outstanding at March 31, 2021: Transaction Number Outstanding as of March 31, 2021 Exercise Price per Share as of March 31, 2021 Blackwell and Silverback warrants 1,000,000 $ 3.25 January 2020 warrant exercise right shares 4,209,608 $ 2.87 April 2019 PIPE warrants 1,381,940 $4.76/$5.02 Naxyris LSA warrants 2,000,000 $ 2.87 October 2019 Naxyris warrant 2,000,000 $ 3.87 May 2019 6.50% Note Exchange warrants 960,225 $ 2.87 May 2017 cash warrants 1,863,056 $ 2.87 May 2017 dilution warrants 3,085,893 $ 0.00 August 2017 dilution warrants 3,028,983 $ 0.00 July 2015 related party debt exchange 58,690 $ 0.15 Other 1,406 $ 160.05 19,589,801 |
Loss Per Share (Tables)
Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted | The following table presents the calculation of basic and diluted loss per share: Three Months Ended March 31, (In thousands, except shares and per share amounts) 2021 2020 Numerator: Net loss attributable to Amyris, Inc. $ (291,251) $ (87,844) Less: losses allocated to participating securities 2,099 1,087 Net loss attributable to Amyris, Inc. common stockholders, basic and diluted $ (289,152) $ (86,757) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted 267,733,555 155,065,635 Loss per share, basic and diluted $ (1.08) $ (0.56) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted loss per share of common stock because including them would have been antidilutive: Three Months Ended March 31, 2021 2020 Period-end common stock warrants 13,416,235 50,518,519 Convertible promissory notes (1) 19,540,447 9,217,185 Period-end stock options to purchase common stock 6,205,576 5,578,264 Period-end restricted stock units 6,653,640 5,298,639 Period-end preferred stock 1,943,661 1,943,661 Total potentially dilutive securities excluded from computation of diluted loss per share 47,759,559 72,556,268 ______________ (1) The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Revenue Recognition and Contr_2
Revenue Recognition and Contract Assets and Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue | The following table presents revenue by major product and service, as well as by primary geographical market, based on the location of the customer: Three Months Ended March 31, (In thousands) 2021 2020 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total United States $ 20,090 $ — $ 250 $ 20,340 $ 11,944 $ — $ — $ 11,944 Europe 2,972 143,800 2,346 149,118 3,242 5,161 3,356 11,759 Asia 4,405 2,284 6,689 2,018 — 2,759 4,777 Brazil 313 313 577 — — 577 Other 399 399 73 — — 73 $ 28,179 $ 143,800 $ 4,880 $ 176,859 $ 17,854 $ 5,161 $ 6,115 $ 29,130 The following table presents revenue by major product and service, as well as by customer type: Three Months Ended March 31, (In thousands) 2021 2020 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total Consumer $ 15,653 $ — $ — $ 15,653 $ 9,065 $ — $ — $ 9,065 Ingredients 12,526 143,800 — 156,326 8,789 5,161 — 13,950 Research and development — — 4,880 4,880 — — 6,115 6,115 $ 28,179 $ 143,800 $ 4,880 $ 176,859 $ 17,854 $ 5,161 $ 6,115 $ 29,130 |
Revenue in Connection with Significant Revenue Agreement | In connection with the significant revenue agreements discussed below and others previously disclosed (see Note 10, “Revenue Recognition” in Part II, Item 8 of the 2020 Form 10-K), the Company recognized the following revenue for the three months ended March 31, 2021 and 2020 : Three Months Ended March 31, (In thousands) 2021 2020 Renewable Products Licenses and Royalties Grants and Collaborations Total Renewable Products Licenses and Royalties Grants and Collaborations Total DSM - related party $ 1,662 $ 143,612 $ 2,000 $ 147,274 $ 49 $ 3,750 $ 3,018 $ 6,817 Sephora 4,441 — — 4,441 4,446 — — 4,446 Yifan — — 2,284 2,284 — — 2,709 2,709 Firmenich 379 188 205 772 1,229 1,411 161 2,801 Givaudan 210 — — 210 2,109 — — 2,109 Subtotal revenue from significant revenue agreements 6,692 143,800 4,489 154,981 7,833 5,161 5,888 18,882 Revenue from all other customers 21,487 — 391 21,878 10,021 — 227 10,248 Total revenue from all customers $ 28,179 $ 143,800 $ 4,880 $ 176,859 $ 17,854 $ 5,161 $ 6,115 $ 29,130 |
Contract with Customer, Asset and Liability | The following table provides information about accounts receivable, contract assets and contract liabilities from contracts with customers: (In thousands) March 31, 2021 December 31, 2020 Accounts receivable, net $ 27,036 $ 32,846 Accounts receivable - related party, net $ 391 $ 12,110 Contract assets $ 6,589 $ 4,178 Contract assets - related party $ 2,000 $ 1,203 Contract liabilities $ 6,163 $ 4,468 Contract liabilities, noncurrent (1) $ 111 $ 111 (1) As of March 31, 2021 and December 31, 2020, contract liabilities, noncurrent is presented in Other noncurrent liabilities in the condensed consolidated balance sheets. |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction | The following table provides information regarding the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) based on the Company's existing agreements with customers as of March 31, 2021. (In thousands) As of March 31, 2021 Remaining 2021 $ 143 2022 3,103 2023 1,430 2024 and thereafter 429 Total from all customers $ 5,105 |
Related Party Transactions (Tab
Related Party Transactions (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Related Party Transactions [Abstract] | |
Schedule of Related Party Debt | Related party debt was as follows: March 31, 2021 December 31, 2020 In thousands Principal Unaccreted Debt Discount Change in Fair Value Net Principal Unaccreted Debt Discount Change in Fair Value Net Foris notes $ 55,041 $ — $ 329,398 $ 384,439 $ 55,041 $ — $ 73,123 $ 128,164 DSM notes 10,000 (4,254) — 5,746 33,000 (2,443) — 30,557 Naxyris note 23,914 (412) — 23,502 23,914 (493) — 23,421 $ 88,955 $ (4,666) $ 329,398 $ 413,687 $ 111,955 $ (2,936) $ 73,123 $ 182,142 |
Schedule of Related Party Accounts Receivables | Related party accounts receivable, contract assets and accounts payable were as follows: (In thousands) March 31, 2021 December 31, 2020 Accounts receivable - related party $ 391 $ 12,110 Contract assets - related party $ 2,000 $ 1,203 Accounts payable $ 10,302 $ 5,011 |
Stock-based Compensation (Table
Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity | The Company’s stock option activity and related information for the three months ended March 31, 2021 was as follows: Quantity of Stock Options Weighted- Weighted-average Aggregate Outstanding - December 31, 2020 6,502,096 $ 7.64 7.6 $ 8,875 Granted 131,408 $ 14.52 Exercised (375,390) $ 5.12 Forfeited or expired (52,538) $ 38.21 Outstanding - March 31, 2021 6,205,576 $ 7.68 7.4 $ 82,615 Vested or expected to vest after March 31, 2021 5,697,447 $ 7.91 7.3 $ 75,493 Exercisable at March 31, 2021 1,259,029 $ 18.19 5.8 $ 12,884 |
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity | The Company’s restricted stock units (RSUs) activity and related information for the three months ended March 31, 2021 was as follows: Quantity of Restricted Stock Units Weighted-average Grant-date Fair Value Weighted-average Remaining Contractual Life, in Years Outstanding - December 31, 2020 7,043,909 $ 4.18 1.5 Awarded 345,903 $ 13.53 Released (496,492) $ 4.34 Forfeited (239,680) $ 4.22 Outstanding - March 31, 2021 6,653,640 $ 4.65 1.4 Vested or expected to vest after March 31, 2021 6,082,165 $ 4.65 1.3 |
Share-based Payment Arrangement, Expensed and Capitalized, Amount | Stock-based compensation expense related to employee and non-employee options, RSUs and ESPP during the three months ended March 31, 2021 and 2020 is reflected in the condensed consolidated statements of operations as follows: Three Months Ended March 31, (In thousands) 2021 2020 Cost of products sold $ 63 $ — Research and development 1,062 1,065 Sales, general and administrative 3,156 2,439 Total stock-based compensation expense $ 4,281 $ 3,504 |
Basis of Presentation and Sum_3
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Accumulated deficit | $ (2,377,943) | $ (2,086,692) |
Balance Sheet Details - Allowan
Balance Sheet Details - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Balance at Beginning of Year | $ 137 | $ 45 |
Provisions | 17 | 0 |
Write-offs, Net | 0 | 0 |
Balance at End of Period | $ 154 | $ 45 |
Balance Sheet Details - Invento
Balance Sheet Details - Inventories (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Raw materials | $ 12,185 | $ 11,800 |
Work-in-process | 8,702 | 10,760 |
Finished goods | 26,752 | 20,302 |
Inventories | $ 47,639 | $ 42,862 |
Balance Sheet Details - Deferre
Balance Sheet Details - Deferred Cost of Products Sold - Related Party (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Deferred cost of products sold - related party | $ 5,220 | $ 9,801 |
Deferred cost of products sold, noncurrent - related party | 9,391 | 9,939 |
Total | $ 14,611 | $ 19,740 |
Balance Sheet Details - Additio
Balance Sheet Details - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 126 Months Ended | ||
Mar. 31, 2021 | Mar. 31, 2020 | Mar. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Line Items] | ||||
Deferred cost of products sold, amortization | $ 4,900 | |||
Right-of-use assets under operating leases, net | $ 9,333 | 9,333 | $ 10,136 | |
Operating lease liability | 13,719 | 13,719 | 15,000 | |
Operating lease expense | 1,800 | $ 1,500 | ||
Lease, cost | 200 | 300 | ||
Finance lease, right-of-use asset amortization | $ 5,300 | $ 5,300 | $ 4,600 | |
Koninklijke DSM N.V (DSM) | ||||
Property, Plant and Equipment [Line Items] | ||||
Supply agreement term (years) | 5 years | |||
Deferred cost of products sold, amortization | $ 1,600 | $ 100 | ||
Minimum | ||||
Property, Plant and Equipment [Line Items] | ||||
Operating lease remaining lease term (years) | 1 year | 1 year | ||
Operating lease renewal term (years) | 1 year | 1 year | ||
Maximum | ||||
Property, Plant and Equipment [Line Items] | ||||
Operating lease remaining lease term (years) | 5 years | 5 years | ||
Operating lease renewal term (years) | 5 years | 5 years |
Balance Sheet Details - Prepaid
Balance Sheet Details - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Prepayments, advances and deposits | $ 13,453 | $ 6,637 |
Non-inventory production supplies | 3,364 | 3,989 |
Recoverable taxes from Brazilian government entities | 1,020 | 1,063 |
Other | 1,409 | 1,414 |
Total prepaid expenses and other current assets | $ 19,246 | $ 13,103 |
Balance Sheet Details - Propert
Balance Sheet Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 112,730 | $ 113,110 |
Less: accumulated depreciation and amortization | (80,797) | (80,235) |
Property, plant and equipment, net | 31,933 | 32,875 |
Machinery and equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 49,880 | 50,415 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 44,800 | 45,197 |
Computers and software | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 7,362 | 6,741 |
Furniture and office equipment, vehicles and land | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 3,450 | 3,507 |
Construction in progress | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 7,238 | $ 7,250 |
Balance Sheet Details - Depreci
Balance Sheet Details - Depreciation and Amortization (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Depreciation and amortization expense | $ 2,114 | $ 1,719 |
Balance Sheet Details - Right-o
Balance Sheet Details - Right-of-use Assets and Related Lease Liabilities (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Cash paid for operating lease liabilities, in thousands | $ 1,185 | $ 1,893 |
Right-of-use assets obtained in exchange for new operating lease obligations, in thousands | $ 0 | $ 0 |
Weighted-average remaining lease term | 2 years 8 months 12 days | 3 years 2 months 12 days |
Weighted-average discount rate | 18.00% | 18.00% |
Balance Sheet Details - Maturit
Balance Sheet Details - Maturities of Financing and Operating Leases (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Financing Leases | ||
2021 (Remaining Nine Months) | $ 3,491 | |
2022 | 0 | |
2023 | 0 | |
2024 | 0 | |
2025 | 0 | |
Total lease payments | 3,491 | |
Less: amount representing interest | (233) | |
Total lease liability | 3,258 | |
Current lease liability | 3,258 | $ 4,170 |
Noncurrent lease liability | 0 | |
Operating Leases | ||
2021 (Remaining Nine Months) | 5,644 | |
2022 | 7,655 | |
2023 | 3,320 | |
2024 | 150 | |
2025 | 0 | |
Total lease payments | 16,769 | |
Less: amount representing interest | (3,050) | |
Total lease liability | 13,719 | 15,000 |
Current lease liability | 5,510 | 5,226 |
Noncurrent lease liability | 8,209 | $ 9,732 |
2021 (Remaining Nine Months) | 9,135 | |
2022 | 7,655 | |
2023 | 3,320 | |
2024 | 150 | |
2025 | 0 | |
Total lease payments | 20,260 | |
Less: amount representing interest | (3,283) | |
Total lease liability | 16,977 | |
Current lease liability | 8,768 | |
Noncurrent lease liability | $ 8,209 |
Balance Sheet Details - Other A
Balance Sheet Details - Other Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Equity-method investment | $ 3,431 | $ 2,380 |
Deposits | 126 | 128 |
Other | 1,213 | 1,196 |
Total other assets | $ 4,770 | $ 3,704 |
Balance Sheet Details - Accrued
Balance Sheet Details - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Accrued interest | $ 7,721 | $ 9,327 |
Payroll and related expenses | 10,540 | 8,230 |
Contract termination fees | 5,311 | 5,344 |
Asset retirement obligation | 3,003 | 3,041 |
Professional services | 1,604 | 994 |
Ginkgo partnership payments obligation | 878 | 878 |
Tax-related liabilities | 639 | 656 |
Other | 2,425 | 2,237 |
Total accrued and other current liabilities | $ 32,121 | $ 30,707 |
Balance Sheet Details - Other N
Balance Sheet Details - Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Liability for unrecognized tax benefit | $ 7,551 | $ 7,496 |
Ginkgo partnership payments obligation, net of current portion | 7,461 | 7,277 |
Liability in connection with acquisition of equity-method investment | 7,216 | 6,771 |
Contract liabilities, net of current portion | 111 | 111 |
Other | 128 | 1,099 |
Total other noncurrent liabilities | $ 22,467 | $ 22,754 |
Fair Value Measurement - Fair V
Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Embedded derivatives bifurcated from debt instruments | $ 188 | $ 247 |
Freestanding derivative instruments issued in connection with other debt and equity instruments | 31,196 | 8,451 |
Total liabilities measured and recorded at fair value | 465,580 | 185,249 |
Foris Convertible Note (LSA Amendment) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt | 379,439 | 123,164 |
Senior Convertible Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt | 54,757 | 53,387 |
Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Embedded derivatives bifurcated from debt instruments | 0 | 0 |
Freestanding derivative instruments issued in connection with other debt and equity instruments | 0 | 0 |
Total liabilities measured and recorded at fair value | 0 | 0 |
Level 1 | Foris Convertible Note (LSA Amendment) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt | 0 | 0 |
Level 1 | Senior Convertible Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt | 0 | 0 |
Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Embedded derivatives bifurcated from debt instruments | 0 | 0 |
Freestanding derivative instruments issued in connection with other debt and equity instruments | 0 | 0 |
Total liabilities measured and recorded at fair value | 0 | 0 |
Level 2 | Foris Convertible Note (LSA Amendment) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt | 0 | 0 |
Level 2 | Senior Convertible Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt | 0 | 0 |
Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Embedded derivatives bifurcated from debt instruments | 188 | 247 |
Freestanding derivative instruments issued in connection with other debt and equity instruments | 31,196 | 8,451 |
Total liabilities measured and recorded at fair value | 465,580 | 185,249 |
Level 3 | Foris Convertible Note (LSA Amendment) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt | 379,439 | 123,164 |
Level 3 | Senior Convertible Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of debt | $ 54,757 | $ 53,387 |
Fair Value Measurement - Fair_2
Fair Value Measurement - Fair Value of Debt — Foris Convertible Note (LSA Amendment) (Details) $ / shares in Units, $ in Thousands | 3 Months Ended | ||
Mar. 31, 2021USD ($)$ / shares | Mar. 31, 2020USD ($) | Dec. 31, 2020USD ($) | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Principal | $ 114,721 | $ 170,504 | |
Long term debt, fair value | 483,465 | 263,059 | |
Loss from change in fair value of debt | (326,785) | $ (16,503) | |
Convertible notes payable | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Principal | |||
Long term debt, fair value | |||
Related party convertible notes payable | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Principal | |||
Long term debt, fair value | |||
Foris Convertible Note (LSA Amendment) | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Loss from change in fair value of debt | $ 256,300 | ||
Foris Convertible Note (LSA Amendment) | Convertible notes payable | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares | $ 3 | ||
Foris Convertible Note (LSA Amendment) | Convertible notes payable | Measurement Input, Stock Price | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Measurement input | 19.10 | ||
Foris Convertible Note (LSA Amendment) | Convertible notes payable | Measurement Input, Discount Rate | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Measurement input | 0.10 | ||
Foris Convertible Note (LSA Amendment) | Convertible notes payable | Risk-free Interest Rate | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Measurement input | 0.0009 | ||
Foris Convertible Note (LSA Amendment) | Convertible notes payable | Stock Price Volatility | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Measurement input | 0.45 | ||
Foris Convertible Note (LSA Amendment) | Convertible notes payable | Probability of Change in Control | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Measurement input | 0.05 | ||
Foris Convertible Note (LSA Amendment) | Related party convertible notes payable | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Principal | $ 50,041 | 50,041 | |
Long term debt, fair value | $ 379,439 | $ 123,164 |
Fair Value Measurement - Fair_3
Fair Value Measurement - Fair Value of Debt — Senior Convertible Notes (Details) $ / shares in Units, $ in Thousands | Mar. 31, 2021USD ($)$ / shares | Dec. 31, 2020USD ($) |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Principal | $ 114,721 | $ 170,504 |
Long term debt, fair value | 483,465 | 263,059 |
Convertible notes payable | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Principal | ||
Long term debt, fair value | ||
Senior convertible notes | Convertible notes payable | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Principal | 10,020 | 30,020 |
Long term debt, fair value | $ 54,757 | $ 53,387 |
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares | $ 3.50 | |
Senior convertible notes | Convertible notes payable | Measurement Input, Stock Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Measurement input | 19.10 | |
Senior convertible notes | Convertible notes payable | Measurement Input, Discount Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Measurement input | 2.10 | |
Senior convertible notes | Convertible notes payable | Risk-free Interest Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Measurement input | 0.0002 | |
Senior convertible notes | Convertible notes payable | Stock Price Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Measurement input | 0.45 | |
Senior convertible notes | Convertible notes payable | Probability of Change in Control | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Measurement input | 0 |
Fair Value Measurement - Fair_4
Fair Value Measurement - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2021USD ($) | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Less: fair value adjustment extinguished upon conversion of debt principal | $ (49,140) |
Long-term Debt | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Fair value, beginning balance | 53,387 |
Loss from change in fair value | 70,510 |
Less: principal converted into common stock | (20,000) |
Fair value, ending balance | $ 54,757 |
Fair Value Measurement - Reconc
Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2021USD ($) | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Derecognition on settlement or extinguishment | $ (49,140) |
Debt-related Derivative Liability | Level 3 | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Fair value, beginning balance | 8,698 |
Change in fair value of derivative instruments | 22,745 |
Derecognition on settlement or extinguishment | (59) |
Fair value, ending balance | $ 31,384 |
Fair Value Measurement - Freest
Fair Value Measurement - Freestanding Derivative Instruments (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | Feb. 28, 2020 | Mar. 31, 2021 |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Exercise price per share (in dollars per share) | $ 3.25 | |
Warrants Issued In Connection with September 2019 and November 2019 Shottenfeld Notes | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Class of warrant or right, number of securities called by warrants or rights (in shares) | 1.9 | |
Exercise price per share (in dollars per share) | $ 2.87 | |
Class of warrant or right, term | 2 years | |
Warrants and rights outstanding, derivative liability | $ 31.2 | |
Fair value adjustment of warrants | $ 22.7 |
Fair Value Measurement - Market
Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details) | Mar. 31, 2021 | Dec. 31, 2020 |
Expected Diviend Yield | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivative liability, measurement input | 0 | 0 |
Minimum | Share Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivative liability, measurement input | 19.10 | 2.56 |
Minimum | Measurement Input, Exercise Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivative liability, measurement input | 2.87 | 2.87 |
Minimum | Stock Price Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivative liability, measurement input | 1.14 | 0.94 |
Minimum | Risk-free Interest Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivative liability, measurement input | 0.000016 | 0.0013 |
Minimum | Measurement Input, Expected Term | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivative liability, measurement input | 2 | 1 |
Maximum | Share Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivative liability, measurement input | 19.10 | 6.18 |
Maximum | Measurement Input, Exercise Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivative liability, measurement input | 2.87 | 3.25 |
Maximum | Stock Price Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivative liability, measurement input | 1.14 | 1.17 |
Maximum | Risk-free Interest Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivative liability, measurement input | 0.000016 | 0.0158 |
Maximum | Measurement Input, Expected Term | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Embedded derivative liability, measurement input | 2 | 2 |
Fair Value Measurement - Financ
Fair Value Measurement - Financial Assets and Liabilities (Details) - USD ($) $ in Millions | Mar. 31, 2021 | Dec. 31, 2020 |
Fair Value Disclosures [Abstract] | ||
Combined debt amount | $ 49.3 | $ 86.5 |
Debt instrument fair value disclosure | $ 51.1 | $ 83.3 |
Debt - Debt Components (Details
Debt - Debt Components (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
Debt Instrument [Line Items] | ||
Principal | $ 114,721 | $ 170,504 |
Unaccreted debt discount | (5,391) | (3,935) |
Debt change in fair value gain loss | 374,135 | 96,490 |
Net | 483,465 | 263,059 |
Less: current portion | (55,904) | (77,437) |
Long-term debt, net of current portion | 427,561 | 185,622 |
Convertible notes payable | ||
Debt Instrument [Line Items] | ||
Principal | ||
Unaccreted debt discount | ||
Debt change in fair value gain loss | ||
Net | ||
Convertible notes payable | Senior convertible notes | ||
Debt Instrument [Line Items] | ||
Principal | 10,020 | 30,020 |
Unaccreted debt discount | 0 | 0 |
Debt change in fair value gain loss | 44,737 | 23,367 |
Net | 54,757 | 53,387 |
Related party convertible notes payable | ||
Debt Instrument [Line Items] | ||
Principal | ||
Unaccreted debt discount | ||
Debt change in fair value gain loss | ||
Net | ||
Related party convertible notes payable | Foris Convertible Note (LSA Amendment) | ||
Debt Instrument [Line Items] | ||
Principal | 50,041 | 50,041 |
Unaccreted debt discount | 0 | 0 |
Debt change in fair value gain loss | 329,398 | 73,123 |
Net | 379,439 | 123,164 |
Loans payable and credit facilities | ||
Debt Instrument [Line Items] | ||
Principal | 15,746 | 28,529 |
Unaccreted debt discount | (725) | (999) |
Debt change in fair value gain loss | 0 | 0 |
Net | 15,021 | 27,530 |
Loans payable and credit facilities | Schottenfeld notes | ||
Debt Instrument [Line Items] | ||
Principal | 0 | 12,500 |
Unaccreted debt discount | 0 | (240) |
Debt change in fair value gain loss | 0 | 0 |
Net | 0 | 12,260 |
Loans payable and credit facilities | Nikko notes | ||
Debt Instrument [Line Items] | ||
Principal | 2,737 | 2,802 |
Unaccreted debt discount | (725) | (759) |
Debt change in fair value gain loss | 0 | 0 |
Net | 2,012 | 2,043 |
Loans payable and credit facilities | Ginkgo note | ||
Debt Instrument [Line Items] | ||
Principal | 12,000 | 12,000 |
Unaccreted debt discount | 0 | 0 |
Debt change in fair value gain loss | 0 | 0 |
Net | 12,000 | 12,000 |
Loans payable and credit facilities | Other loans payable | ||
Debt Instrument [Line Items] | ||
Principal | 1,009 | 1,227 |
Unaccreted debt discount | 0 | 0 |
Debt change in fair value gain loss | 0 | 0 |
Net | 1,009 | 1,227 |
Related party loans payable | ||
Debt Instrument [Line Items] | ||
Principal | 38,914 | 61,914 |
Unaccreted debt discount | (4,666) | (2,936) |
Debt change in fair value gain loss | 0 | 0 |
Net | 34,248 | 58,978 |
Related party loans payable | Foris note | ||
Debt Instrument [Line Items] | ||
Principal | 5,000 | 5,000 |
Unaccreted debt discount | 0 | 0 |
Debt change in fair value gain loss | 0 | 0 |
Net | 5,000 | 5,000 |
Related party loans payable | DSM notes | ||
Debt Instrument [Line Items] | ||
Principal | 10,000 | 33,000 |
Unaccreted debt discount | (4,254) | (2,443) |
Debt change in fair value gain loss | 0 | 0 |
Net | 5,746 | 30,557 |
Related party loans payable | Naxyris note | ||
Debt Instrument [Line Items] | ||
Principal | 23,914 | 23,914 |
Unaccreted debt discount | (412) | (493) |
Debt change in fair value gain loss | 0 | 0 |
Net | $ 23,502 | $ 23,421 |
Debt - Future Minimum Payments
Debt - Future Minimum Payments (Details) $ in Thousands | Mar. 31, 2021USD ($) |
Debt Instrument [Line Items] | |
2021 (Remaining Nine Months) | $ 16,231 |
2022 | 115,225 |
2023 | 399 |
2024 | 398 |
2025 | 397 |
Thereafter | 1,473 |
Total future minimum payments | 134,123 |
Less: amount representing interest | (19,402) |
Present value of minimum debt payments | 114,721 |
Less: current portion of debt principal | (11,300) |
Noncurrent portion of debt principal | 103,421 |
Convertible notes payable | |
Debt Instrument [Line Items] | |
2021 (Remaining Nine Months) | 11,189 |
2022 | 0 |
2023 | 0 |
2024 | 0 |
2025 | 0 |
Thereafter | 0 |
Total future minimum payments | 11,189 |
Less: amount representing interest | (1,169) |
Present value of minimum debt payments | 10,020 |
Less: current portion of debt principal | (10,020) |
Noncurrent portion of debt principal | 0 |
Loans Payable and Credit Facilities | |
Debt Instrument [Line Items] | |
2021 (Remaining Nine Months) | 2,260 |
2022 | 13,268 |
2023 | 399 |
2024 | 398 |
2025 | 397 |
Thereafter | 1,473 |
Total future minimum payments | 18,195 |
Less: amount representing interest | (2,449) |
Present value of minimum debt payments | 15,746 |
Less: current portion of debt principal | (1,280) |
Noncurrent portion of debt principal | 14,466 |
Related party convertible notes payable | |
Debt Instrument [Line Items] | |
2021 (Remaining Nine Months) | 0 |
2022 | 59,578 |
2023 | 0 |
2024 | 0 |
2025 | 0 |
Thereafter | 0 |
Total future minimum payments | 59,578 |
Less: amount representing interest | (9,537) |
Present value of minimum debt payments | 50,041 |
Less: current portion of debt principal | 0 |
Noncurrent portion of debt principal | 50,041 |
Related Party Loans Payable and Credit Facilities | |
Debt Instrument [Line Items] | |
2021 (Remaining Nine Months) | 2,782 |
2022 | 42,379 |
2023 | 0 |
2024 | 0 |
2025 | 0 |
Thereafter | 0 |
Total future minimum payments | 45,161 |
Less: amount representing interest | (6,247) |
Present value of minimum debt payments | 38,914 |
Less: current portion of debt principal | 0 |
Noncurrent portion of debt principal | $ 38,914 |
Debt - Senior Convertible Notes
Debt - Senior Convertible Notes (Details) - USD ($) | Mar. 01, 2021 | Feb. 04, 2021 | Mar. 31, 2021 | Mar. 31, 2020 |
Debt Instrument [Line Items] | ||||
Gain (loss) on extinguishment of debt | $ (28,900,000) | $ 27,313,000 | $ 27,319,000 | |
Senior convertible notes | Convertible notes payable | ||||
Debt Instrument [Line Items] | ||||
Debt instrument, face amount | $ 20,000,000 | |||
Conversion of convertible securities | $ 5,700,000 | |||
Shares to be returned per agreement (in shares) | 2,600,000 | 2,600,000 | ||
Shares issued for conversion settlement (in shares) | 3,100,000 | |||
Gain (loss) on extinguishment of debt | $ 31,900,000 |
Debt - Schottfield Debt (Detail
Debt - Schottfield Debt (Details) - USD ($) $ in Thousands, shares in Millions | Mar. 01, 2021 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 |
Debt Instrument [Line Items] | ||||
Principal | $ 114,721 | $ 170,504 | ||
Conversion of stock, shares issued | 4.1 | |||
Loss upon extinguishment of debt | $ 28,900 | $ (27,313) | $ (27,319) | |
Schottenfeld Exchange Agreement | ||||
Debt Instrument [Line Items] | ||||
Principal | $ 12,500 |
Debt - DSM Amendments and Repay
Debt - DSM Amendments and Repayment (Details) | Dec. 28, 2017USD ($) | Mar. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Sep. 17, 2019USD ($)installment |
Debt Instrument [Line Items] | ||||
Principal | $ 114,721,000 | $ 170,504,000 | ||
Number of installments | installment | 3 | |||
The 2019 DSM Credit Agreement | DSM - related party | ||||
Debt Instrument [Line Items] | ||||
Line of credit facility, maximum borrowing capacity | $ 8,000,000 | |||
DSM Credit Agreement | ||||
Debt Instrument [Line Items] | ||||
Line of credit facility, maximum borrowing capacity | $ 25,000,000 | |||
Proceeds from long-term lines of credit | $ 25,000,000 | |||
Debt instrument, interest rate, stated percentage | 10.00% | 12.50% | ||
DSM Credit Agreement | Unsecured Debt | ||||
Debt Instrument [Line Items] | ||||
Line of credit facility, maximum borrowing capacity | $ 25,000,000 | $ 8,000,000 | ||
Principal | 10,000,000 | |||
Debt instrument, unamortized discount | 2,500,000 | |||
Extinguishment of debt, amount | 8,000,000 | |||
DSM Credit Agreement - March 2021 Amendment | Unsecured Debt | ||||
Debt Instrument [Line Items] | ||||
Principal | 10,000,000 | |||
Debt instrument, unamortized discount | 2,500,000 | |||
Repayments of debt | 23,000,000 | |||
DSM Credit Agreement - March 2021 Amendment Related To 25 Million Dollar Note | Unsecured Debt | ||||
Debt Instrument [Line Items] | ||||
Extinguishment of debt, amount | $ 15,000,000 |
Mezzanine Equity (Details Textu
Mezzanine Equity (Details Textual) - Gates Foundation Purchase Agreement $ / shares in Units, $ in Millions | 3 Months Ended |
Mar. 31, 2021USD ($)$ / shares | |
Subsidiary, Sale of Stock [Line Items] | |
Stock price (in dollars per share) | $ / shares | $ 17.10 |
Compound annual return (percentage) | 10.00% |
Research and development obligation, remaining amount | $ | $ 0.3 |
Stockholders' Deficit - Warrant
Stockholders' Deficit - Warrant Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 19,589,801 | |
Exercise price per share (in dollars per share) | $ 3.25 | |
Exercises (in shares) | (24,800,000) | |
Exercise price per share of warrant exercised (in dollars per share) | $ 3.06 | |
Proceeds from exercises of warrants | $ 32,219 | $ 3,332 |
Additional warrants issued (in shares) | 21,600,000 | |
Blackwell and Silverback warrants | ||
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 1,000,000 | |
January 2020 warrant exercise right shares | ||
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 4,209,608 | |
Exercise price per share (in dollars per share) | $ 2.87 | |
April 2019 PIPE warrants | ||
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 1,381,940 | |
April 2019 PIPE warrants | Minimum | ||
Class of Warrant or Right [Line Items] | ||
Exercise price per share (in dollars per share) | $ 4.76 | |
April 2019 PIPE warrants | Maximum | ||
Class of Warrant or Right [Line Items] | ||
Exercise price per share (in dollars per share) | $ 5.02 | |
Naxyris LSA warrants | ||
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 2,000,000 | |
Exercise price per share (in dollars per share) | $ 2.87 | |
October 2019 Naxyris warrant | ||
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 2,000,000 | |
Exercise price per share (in dollars per share) | $ 3.87 | |
May 2019 6.50% Note Exchange warrants | ||
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 960,225 | |
Exercise price per share (in dollars per share) | $ 2.87 | |
May 2017 cash warrants | ||
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 1,863,056 | |
Exercise price per share (in dollars per share) | $ 2.87 | |
May 2017 dilution warrants | ||
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 3,085,893 | |
Exercise price per share (in dollars per share) | $ 0 | |
August 2017 dilution warrants | ||
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 3,028,983 | |
Exercise price per share (in dollars per share) | $ 0 | |
July 2015 related party debt exchange | ||
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 58,690 | |
Exercise price per share (in dollars per share) | $ 0.15 | |
Other | ||
Class of Warrant or Right [Line Items] | ||
Class of warrant or right, outstanding (in shares) | 1,406 | |
Exercise price per share (in dollars per share) | $ 160.05 |
Net Loss Per Share Attributab_2
Net Loss Per Share Attributable to Common Shareholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Numerator: | ||
Net loss attributable to Amyris, Inc. | $ (291,251) | $ (87,844) |
Less: losses allocated to participating securities | 2,099 | 1,087 |
Net Income (Loss) Available to Common Stockholders, Basic, Total | $ (289,152) | $ (86,757) |
Denominator: | ||
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares) | 267,733,555 | 155,065,635 |
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares) | 267,733,555 | 155,065,635 |
Loss per share attributable to common stockholders, diluted (in dollars per share) | $ (1.08) | $ (0.56) |
Loss per share attributable to common stockholders, basic (in dollars per share) | $ (1.08) | $ (0.56) |
Net Loss Per Share Attributab_3
Net Loss Per Share Attributable to Common Shareholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) | 47,759,559,000 | 72,556,268,000 |
Period-end common stock warrants | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) | 13,416,235,000 | 50,518,519,000 |
Convertible promissory notes | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) | 19,540,447,000 | 9,217,185,000 |
Period-end stock options to purchase common stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) | 6,205,576,000 | 5,578,264,000 |
Period-end restricted stock units | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) | 6,653,640,000 | 5,298,639,000 |
Period-end preferred stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total potentially dilutive securities excluded from computation of diluted loss per share (in shares) | 1,943,661,000 | 1,943,661,000 |
Commitments and Contingencies -
Commitments and Contingencies - Guarantor Arrangements (Details) $ in Millions | Mar. 31, 2021USD ($) |
Aprinnova JV [Member] | |
Loss Contingencies [Line Items] | |
Percentage of venture owned | 10.00% |
Nikko notes | Loans payable and credit facilities | |
Loss Contingencies [Line Items] | |
Debt instrument, face amount | $ 3.9 |
Revenue Recognition and Contr_3
Revenue Recognition and Contract Assets and Liabilities - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Disaggregation of Revenue [Line Items] | ||
Revenue | $ 176,859 | $ 29,130 |
Consumer | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 15,653 | 9,065 |
Ingredients | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 156,326 | 13,950 |
Research and development | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 4,880 | 6,115 |
United States | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 20,340 | 11,944 |
Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 149,118 | 11,759 |
Asia | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 6,689 | 4,777 |
Brazil | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 313 | 577 |
Other | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 399 | 73 |
Renewable Products | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 28,179 | 17,854 |
Renewable Products | Consumer | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 15,653 | 9,065 |
Renewable Products | Ingredients | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 12,526 | 8,789 |
Renewable Products | Research and development | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Renewable Products | United States | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 20,090 | 11,944 |
Renewable Products | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 2,972 | 3,242 |
Renewable Products | Asia | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 4,405 | 2,018 |
Renewable Products | Brazil | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 313 | 577 |
Renewable Products | Other | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 399 | 73 |
Licenses and Royalties | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 143,800 | 5,161 |
Licenses and Royalties | Consumer | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Licenses and Royalties | Ingredients | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 143,800 | 5,161 |
Licenses and Royalties | Research and development | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Licenses and Royalties | United States | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Licenses and Royalties | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 143,800 | 5,161 |
Licenses and Royalties | Asia | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | |
Licenses and Royalties | Brazil | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | |
Licenses and Royalties | Other | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | |
Grants and Collaborations | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 4,880 | 6,115 |
Grants and Collaborations | Consumer | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Grants and Collaborations | Ingredients | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Grants and Collaborations | Research and development | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 4,880 | 6,115 |
Grants and Collaborations | United States | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 250 | 0 |
Grants and Collaborations | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 2,346 | 3,356 |
Grants and Collaborations | Asia | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 2,284 | 2,759 |
Grants and Collaborations | Brazil | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | |
Grants and Collaborations | Other | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | $ 0 |
Revenue Recognition and Contr_4
Revenue Recognition and Contract Assets and Liabilities - Revenue in Connection With Significant Revenue Agreement (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Disaggregation of Revenue [Line Items] | ||
Revenue | $ 176,859 | $ 29,130 |
Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 154,981 | 18,882 |
DSM - related party | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 147,274 | 6,817 |
Sephora | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 4,441 | 4,446 |
Yifan | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 2,284 | 2,709 |
Firmenich | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 772 | 2,801 |
Givaudan | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 210 | 2,109 |
Revenue from all other customers | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 21,878 | 10,248 |
Renewable Products | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 28,179 | 17,854 |
Renewable Products | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 6,692 | 7,833 |
Renewable Products | DSM - related party | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 1,662 | 49 |
Renewable Products | Sephora | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 4,441 | 4,446 |
Renewable Products | Yifan | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Renewable Products | Firmenich | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 379 | 1,229 |
Renewable Products | Givaudan | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 210 | 2,109 |
Renewable Products | Revenue from all other customers | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 21,487 | 10,021 |
Licenses and Royalties | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 143,800 | 5,161 |
Licenses and Royalties | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 143,800 | 5,161 |
Licenses and Royalties | DSM - related party | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 143,612 | 3,750 |
Licenses and Royalties | Sephora | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Licenses and Royalties | Yifan | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Licenses and Royalties | Firmenich | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 188 | 1,411 |
Licenses and Royalties | Givaudan | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Licenses and Royalties | Revenue from all other customers | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Grants and Collaborations | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 4,880 | 6,115 |
Grants and Collaborations | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 4,489 | 5,888 |
Grants and Collaborations | DSM - related party | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 2,000 | 3,018 |
Grants and Collaborations | Sephora | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Grants and Collaborations | Yifan | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 2,284 | 2,709 |
Grants and Collaborations | Firmenich | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 205 | 161 |
Grants and Collaborations | Givaudan | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | 0 | 0 |
Grants and Collaborations | Revenue from all other customers | Significant Revenue Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | $ 391 | $ 227 |
Revenue Recognition and Contr_5
Revenue Recognition and Contract Assets and Liabilities - Contract Balances (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Revenue from Contract with Customer [Abstract] | ||
Accounts receivable, net | $ 27,036 | $ 32,846 |
Accounts receivable - related party, net | 391 | 12,110 |
Contract assets | 6,589 | 4,178 |
Contract assets - related party | 2,000 | 1,203 |
Contract liabilities | 6,163 | 4,468 |
Contract liabilities, noncurrent | $ 111 | $ 111 |
Revenue Recognition and Contr_6
Revenue Recognition and Contract Assets and Liabilities - Remaining Performance Obligations (Details) $ in Thousands | Mar. 31, 2021USD ($) |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, Amount | $ 5,105 |
Constrained variable consideration amount | $ 297,800 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 9 months |
Revenue, remaining performance obligation, Amount | $ 143 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Revenue, remaining performance obligation, Amount | $ 3,103 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Revenue, remaining performance obligation, Amount | $ 1,430 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, expected timing of satisfaction, period | |
Revenue, remaining performance obligation, Amount | $ 429 |
Revenue Recognition and Contr_7
Revenue Recognition and Contract Assets and Liabilities - DSM License Agreement and Contract Asset (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Disaggregation of Revenue [Line Items] | ||
Revenue | $ 176,859 | $ 29,130 |
DSM - related party | Maximum | ||
Disaggregation of Revenue [Line Items] | ||
Contingent considerations, maximum | 235,000 | |
DSM - related party | DSM License Agreement | ||
Disaggregation of Revenue [Line Items] | ||
Estimated total unconstrained transaction price | $ 150,000 | |
Supply agreement term (years) | 15 years | |
DSM - related party | DSM License Agreement | License | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | $ 143,600 | |
DSM - related party | DSM License Agreement | Finished Goods Inventory | ||
Disaggregation of Revenue [Line Items] | ||
Estimated total unconstrained transaction price | 1,500 | |
DSM - related party | DSM License Agreement | Receivables | ||
Disaggregation of Revenue [Line Items] | ||
Estimated total unconstrained transaction price | 4,900 | |
DSM - related party | DSM License Agreement | Intellectual Property License | ||
Disaggregation of Revenue [Line Items] | ||
Estimated total unconstrained transaction price | $ 143,600 |
Revenue Recognition and Contr_8
Revenue Recognition and Contract Assets and Liabilities - DSM Performance Agreement (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | |
Dec. 31, 2017 | Mar. 31, 2021 | Mar. 31, 2020 | |
Disaggregation of Revenue [Line Items] | |||
Research and development | $ 23,332 | $ 17,126 | |
Research and development | DSM Performance Collabration | DSM - related party | |||
Disaggregation of Revenue [Line Items] | |||
Contingent considerations, maximum | $ 1,900 | ||
Estimated total unconstrained transaction price | $ 1,200 | ||
Contingent consideration received | 1,900 | ||
Research and development | $ 1,900 |
Revenue Recognition and Contr_9
Revenue Recognition and Contract Assets and Liabilities - DSM Ingredients Collaboration (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Disaggregation of Revenue [Line Items] | ||
Revenue | $ 176,859 | $ 29,130 |
DSM - related party | DSM Ingredients Collaboration | ||
Disaggregation of Revenue [Line Items] | ||
Quarterly payments | 2,000 | |
DSM - related party | DSM Ingredients Collaboration | Research and development | ||
Disaggregation of Revenue [Line Items] | ||
Revenue | $ 2,000 | $ 3,000 |
Revenue Recognition and Cont_10
Revenue Recognition and Contract Assets and Liabilities - Yifan Agreement (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Including Assessed Tax | $ 176,859 | $ 29,130 | |
Contract assets | 6,589 | $ 4,178 | |
Significant Revenue Agreement | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Including Assessed Tax | 154,981 | 18,882 | |
Grants and Collaborations | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Including Assessed Tax | 4,880 | 6,115 | |
Grants and Collaborations | Significant Revenue Agreement | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Including Assessed Tax | 4,489 | 5,888 | |
Yifan | Significant Revenue Agreement | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Including Assessed Tax | 2,284 | 2,709 | |
Yifan | Grants and Collaborations | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from contract with customer, cumulative to date | 16,600 | ||
Contract assets | 5,900 | ||
Yifan | Grants and Collaborations | Significant Revenue Agreement | |||
Disaggregation of Revenue [Line Items] | |||
Revenue from Contract with Customer, Including Assessed Tax | $ 2,284 | $ 2,709 |
Related Party Transactions - Re
Related Party Transactions - Related Party Debt (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Related Party Transaction [Line Items] | ||
Principal | $ 114,721 | $ 170,504 |
Net | 483,465 | 263,059 |
Related Party Debt | ||
Related Party Transaction [Line Items] | ||
Principal | 88,955 | 111,955 |
Unaccreted Debt Discount | (4,666) | (2,936) |
Change in Fair Value | 329,398 | 73,123 |
Net | 413,687 | 182,142 |
Foris notes | Related Party Debt | Foris note | ||
Related Party Transaction [Line Items] | ||
Principal | 55,041 | 55,041 |
Unaccreted Debt Discount | 0 | 0 |
Change in Fair Value | 329,398 | 73,123 |
Net | 384,439 | 128,164 |
DSM notes | Related Party Debt | DSM notes | ||
Related Party Transaction [Line Items] | ||
Principal | 10,000 | 33,000 |
Unaccreted Debt Discount | (4,254) | (2,443) |
Change in Fair Value | 0 | 0 |
Net | 5,746 | 30,557 |
Naxyris note | Related Party Debt | Naxyris note | ||
Related Party Transaction [Line Items] | ||
Principal | 23,914 | 23,914 |
Unaccreted Debt Discount | (412) | (493) |
Change in Fair Value | 0 | 0 |
Net | $ 23,502 | $ 23,421 |
Related Party Transactions - _2
Related Party Transactions - Related Party Accounts Receivable (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Related Party Transaction [Line Items] | ||
Accounts payable | $ 0 | $ 22,689 |
DSM notes | Accounts receivable - related party | ||
Related Party Transaction [Line Items] | ||
Accounts receivable, unbilled, related party | 391 | 12,110 |
DSM notes | Contract assets - related party | ||
Related Party Transaction [Line Items] | ||
Accounts receivable, unbilled, related party | 2,000 | 1,203 |
DSM notes | Accounts payable | ||
Related Party Transaction [Line Items] | ||
Accounts payable | $ 10,302 | $ 5,011 |
Stock-based Compensation - Shar
Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
Quantity of Stock Options | ||
Outstanding, beginning balance (in shares) | 6,502,096 | |
Granted (in shares) | 131,408 | |
Exercised (in shares) | (375,390) | |
Forfeited or expired (in shares) | (52,538) | |
Outstanding, ending balance (in shares) | 6,205,576 | 6,502,096 |
Vested or expected to vest (in shares) | 5,697,447 | |
Exercisable (in shares) | 1,259,029 | |
Weighted- average Exercise Price | ||
Outstanding, beginning balance (in dollars per share) | $ 7.64 | |
Granted (in dollars per share) | 14.52 | |
Exercised (in dollars per share) | 5.12 | |
Forfeited or expired (in dollars per share) | 38.21 | |
Outstanding, ending balance (in dollars per share) | 7.68 | $ 7.64 |
Vested or expected to vest (in dollars per share) | 7.91 | |
Exercisable (in dollars per share) | $ 18.19 | |
Weighted-average Remaining Contractual Life, in Years | ||
Outstanding (years) | 7 years 4 months 24 days | 7 years 7 months 6 days |
Vested or expected to vest (years) | 7 years 3 months 18 days | |
Exercisable (years) | 5 years 9 months 18 days | |
Aggregate Intrinsic Value, in Thousands | ||
Outstanding (years) | $ 82,615 | $ 8,875 |
Vested or expected to vest | 75,493 | |
Exercisable | $ 12,884 |
Stock-based Compensation - Temp
Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
Quantity of Restricted Stock Units | ||
Outstanding , beginning balance (in shares) | 7,043,909 | |
Awarded (in shares) | 345,903 | |
Released (in shares) | (496,492) | |
Forfeited (in shares) | (239,680) | |
Outstanding, ending balance (in shares) | 6,653,640 | 7,043,909 |
Vested or expected to vest (in shares) | 6,082,165 | |
Weighted-average Grant-date Fair Value | ||
Outstanding, beginning balance (in dollars per share) | $ 4.18 | |
Awarded (in dollars per share) | 13.53 | |
Released (in dollars per share) | 4.34 | |
Forfeited (in dollars per share) | 4.22 | |
Outstanding, ending balance (in dollars per share) | 4.65 | $ 4.18 |
Vested or expected to vest (in dollars per share) | $ 4.65 | |
Weighted-average Remaining Contractual Life, in Years | ||
Outstanding, beginning balance (years) | 1 year 4 months 24 days | 1 year 6 months |
Outstanding, ending balance (years) | 1 year 4 months 24 days | 1 year 6 months |
Vested or expected to vest (years) | 1 year 3 months 18 days |
Stock-based Compensation - Empl
Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total stock-based compensation expense | $ 4,281 | $ 3,504 |
Cost of products sold | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total stock-based compensation expense | 63 | 0 |
Research and development | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total stock-based compensation expense | 1,062 | 1,065 |
Sales, general and administrative | ||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Total stock-based compensation expense | $ 3,156 | $ 2,439 |
Stock-based Compensation - Addi
Stock-based Compensation - Additional Information (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2021USD ($)shares | |
Employee Stock Option | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Compensation expense related to stock options and RSUs | $ | $ 30 |
Weighted-average period | 2 years 4 months 24 days |
2020 Equity Incentive Plan | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Automatic annual increase available for grant and issuance (in shares) | 12,247,572 |
Automatic annual increase in shares available for grant and issuance, percentage of outstanding stock | 5.00% |
Equity Incentive Plan, 2010 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Automatic annual increase reserved for issuance (in shares) | 42,077 |
Remaining number of shares reserved for issuance, maximum limit | 1,666,666 |
Subsequent Events - Primary and
Subsequent Events - Primary and Secondary Offering (Details) - USD ($) $ / shares in Units, $ in Millions | Apr. 08, 2021 | Mar. 31, 2021 | Dec. 31, 2020 |
Subsequent Event [Line Items] | |||
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |
Subsequent Event | |||
Subsequent Event [Line Items] | |||
Shares issued (in dollars per share) | $ 15.75 | ||
Allotment option agreement, term | 30 days | ||
Issuance of common stock in public offering (in shares) | 8,805,345 | ||
Purchase price of sale of stock | $ 130.7 | ||
Subsequent Event | Public Stock Offering - Shares from Selling Stockholders | |||
Subsequent Event [Line Items] | |||
Number of shares issued in sale of stock (in shares) | 11,390,797 | ||
Common stock, par value (in dollars per share) | $ 0.0001 | ||
Subsequent Event | Public Stock Offering - Shares from Amyris | |||
Subsequent Event [Line Items] | |||
Number of shares issued in sale of stock (in shares) | 7,656,822 | ||
Subsequent Event | Public Stock Offering - Selling Stockholders Underwriting Agreement | |||
Subsequent Event [Line Items] | |||
Number of shares issued in sale of stock (in shares) | 1,708,619 | ||
Subsequent Event | Public Stock Offering - Amyris Underwriting Agreement | |||
Subsequent Event [Line Items] | |||
Number of shares issued in sale of stock (in shares) | 1,148,523 |